---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description. Covers Product description and Place of product in therapy. 231 evidence topics quoted from 121 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Submission planned; BLA planned on the basis of the phase 3 CAPTIVATE trial, with Part B top-line results expected by the end of 2028

> “Top-line results from all participants completing Part A of this trial are expected by the end of 2027, and top-line results from Part B of this trial are expected by the end of 2028. We believe that this single pivotal trial will support a Biologics License Application”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “Top-line results from all participants completing Part A are expected by YE’27, and top-line results from Part B are expected by YE’28.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

> “Single pivotal two-part, randomized withdrawal, double-blind, placebo- controlled trial designed to support BLA in adult patients with CIDP”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Investigational status

> “Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="topic-2.1.1-4"></a>

##### Single pivotal phase 3 trial announced, November 2024

> “We believe this single, two-part, pivotal Phase 3 trial will support BLA filing in adult patients with CIDP and we anticipate initiating the trial by year-end 2024,”
> “Dianthus plans to initiate a single, two-part, randomized withdrawal Phase 3 trial of DNTH103 in CIDP by YE’24.”

Source: [Dianthus Therapeutics (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024123255/dnth-ex99_1.htm)

<a id="topic-2.1.1-5"></a>

##### Phase 3 CAPTIVATE trial initiated, February 2025

> “We are excited to have initiated our pivotal Phase 3 CAPTIVATE trial in CIDP, which is on track for an interim responder analysis in 2H’26, along with top-line results from our Phase 2 trial in MMN.”

Source: [Dianthus Therapeutics (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/dnth-ex99_1.htm)

> “Study Start (Actual) 2025-02-10”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.1-6"></a>

##### Interim responder analysis: early GO decision, March 2026

> “This GO decision was reached early, after 20 confirmed responders were achieved with less than 40 planned participants completing Part A of the trial.”
> “The GO decision was confirmed by an independent DSMB review.”

Source: [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm)

<a id="topic-2.1.1-7"></a>

##### Trial resizing and removal of the 600 mg arm from Part B

> “engage with regulators to remove the claseprubart 600mg/4mL S.C. Q2W arm from Part B; and enroll up to 256 patients (previously up to 480) in Part A to randomize 128 patients in Part B (previously 192).”

Source: [Dianthus Therapeutics Form 10-Q (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000022/dnth-20260331.htm)

> “In November 2026, we announced that the CAPTIVATE trial is now conservatively projected to require less than 200 participants in the open-label Part A in order to randomize 128 responders into the placebo-controlled withdrawal Part B portion of the study.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-2.1.1-8"></a>

##### FDA written feedback on antinuclear antibody screening and drug-induced lupus, March 2026

> “Removal of anti-nuclear antibodies ("ANAs") as a screening criteria, a common reason for screen failure across all three claseprubart programs”
> “Removal of routine ANA testing during claseprubart clinical trials”
> “Reclassification of the hypothetical risk of systemic lupus erythematosus ("SLE") to drug-induced lupus ("DIL")”
> “In March 2026, the Company received written feedback from FDA agreeing to all three of these proposals for all ongoing and planned future claseprubart trials.”

Source: [Dianthus Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm)

<a id="topic-2.1.1-9"></a>

##### Orphan drug, fast track, or breakthrough therapy designation for CIDP

No evidence found.

<a id="topic-2.1.1-10"></a>

##### Other indications in development

> “Dianthus is building a neuromuscular franchise with claseprubart and expects to report top-line results from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in December ’26, report top-line results from the Phase 3 CAPTIVATE trial Part A in CIDP by YE’27 and from Part B by YE’28, and report top-line results from the Phase 3 EMERGE trial in generalized Myasthenia Gravis in 2H’28.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Dianthus Therapeutics

> “Our most advanced product candidate, claseprubart, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “About Claseprubart (DNTH103) Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="topic-2.1.2.1-2"></a>

###### Nonproprietary name: proposed and recommended international nonproprietary name

> “claseprubart”
> “immunoglobulin G4-kappa, anti-[Homo sapiens C1S (complement C1s)], Homo sapiens monoclonal antibody”

Source: [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

> “RECOMMENDED International Nonproprietary Names: List 94”
> “immunoglobulin G4-kappa, anti-[Homo sapiens C1S (complement C1s)], Homo sapiens monoclonal antibody”

Source: [WHO Drug Information Recommended INN List 94 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl94.pdf)

<a id="topic-2.1.2.1-3"></a>

###### Development code

> “Drug: Claseprubart IV Infusion Other Names: DNTH103”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.1-4"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-5"></a>

###### Structure: fully human IgG4-kappa antibody with an engineered Fc domain

> “Claseprubart is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “hinge 1-12 S10>P (225)”
> “M15.1>Y (249), S16>T (251), T18>E (253)”
> “produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa”

Source: [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

<a id="topic-2.1.2.1-6"></a>

###### Therapeutic class: classical complement pathway inhibitor targeting active C1s

> “Highly potent, ~8-week half-life, Classical Pathway (CP) inhibitor targeting active C1s”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Intravenous loading dose followed by subcutaneous injection

> “Dosing: 15 or 20mg/kg I.V. Loading Dose followed by 300mg/2mL or 600mg/4mL S.C. Q2W starting Day 7”
> “Target dose of 300mg/2mL Q2W will be in Ph. 3 study”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Claseprubart intravenous (IV) loading dose on Day 1. Claseprubart subcutaneous (SC) once every 2 weeks for up to 13 weeks.”
> “Drug: Claseprubart IV Infusion”
> “Drug: Claseprubart SC injection”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.2-2"></a>

###### Phase 3 subcutaneous presentation: prefilled syringe

> “Combination Product: Claseprubart Prefilled syringe containing claseprubart for SC administration”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.2-3"></a>

###### Target commercial presentation: 300 mg/2 mL autoinjector

> “Targeting convenience of a single, self-administered S.C. 300mg/2mL autoinjector dosed every 2 or 4 weeks”
> “Targeting single 300mg/2mL self-administered S.C. Q2W”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO INN class statement for claseprubart

> “claseprubart”
> “immunosuppressant”

Source: [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

<a id="topic-2.1.2.4-2"></a>

###### WHO INN stem and target-class infix for monoclonal antibodies

> “The suffix is preceded by an infix that indicates the target class.”
> “The suffix -bart is used for monospecific full-length immunoglobulins with engineered amino acid changes in the constant regions and identical sets of CDRs that recognize the same epitope.”
> “altered neonatal Fc receptor (FcRn) binding”
> “-pru- immunosuppressive”

Source: [WHO INN monoclonal antibody nomenclature scheme (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/new_mab_nomenclature-_2021rev.pdf)

<a id="topic-2.1.2.4-3"></a>

###### WHO Anatomical Therapeutic Chemical group for complement inhibitors

| ATC code | Name |
| --- | --- |
| “L04AJ” | “Complement inhibitors” |
| “L04AJ01” | “eculizumab” |
| “L04AJ02” | “ravulizumab” |
| “L04AJ04” | “sutimlimab” |
| “L04AJ06” | “zilucoplan” |

Source: [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L04AJ)

<a id="topic-2.1.2.4-4"></a>

###### AHFS class and ATC code assigned to claseprubart

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication under study: adults with CIDP

> “The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

> “The CAPTIVATE trial is a single, two-part, randomized withdrawal global Phase 3 trial of claseprubart in patients with CIDP.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-2.1.2.5-2"></a>

###### Eligible population: phase 3 CAPTIVATE inclusion criteria

> “Confirmed diagnosis of CIDP or possible CIDP. Participants must have either typical CIDP or one of the following variants: motor or multifocal CIDP. Diagnosis must be confirmed by the Independent CIDP Review Panel. CIDP Disease Activity Status (CDAS) score ≥ 3 at screening. Must be neurologically stable. Must have an INCAT score between 2 and 9 inclusive.”
> “Currently treated with and responded to immunoglobulin (Ig) (intravenous immunoglobulin [IVIg] or subcutaneous immunoglobulin [SCIg]) alone or Ig (IVIg or SCIg) plus oral corticosteroids”
> “Currently treated with and responded to oral corticosteroids alone or oral corticosteroids in combination with azathioprine or mycophenolate mofetil.”
> “Refractory participants who have had treatment failure (worsening) or an inadequate response to Ig and/or oral corticosteroids”
> “Treatment naïve with no history of prior treatment for CIDP.”
> “Ages Eligible for Study 18 Years to 75 Years”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.5-3"></a>

###### Patient groups enrolled: treated, refractory, and treatment-naive

> “Evaluating claseprubart in SoC- Refractory CIDP patients, in addition to a broader CIDP patient population including SoC-Treated and SoC-Naïve”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Patients aged 18–75 years with confirmed CIDP are administered an IV loading dose of claseprubart followed by 300mg SC Q2W in Part A.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Selective binding to the active form of C1s

> “Our most advanced product candidate, claseprubart, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. The active form of C1s is generated during complement activation by cleavage of the inactive proC1s. As a validated complement target in the autoimmune and inflammatory field, C1s inhibition prevents further progression of the classical pathway cascade.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Role of C1s in the classical complement pathway

> “Classical pathway activation is initiated by the C1 complex. The C1 complex consists of a binding protein, C1q, and two inactive proenzymes, C1r”
> “Initiation of the classical pathway cascade occurs when C1q binds to the Fc portion of immunoglobulin G”
> “In its active form, C1s is responsible for cleaving and activating C4 and C2, which leads to the downstream cascade that culminates in the terminal pathway and MAC formation. C1s is unique to the classical pathway and thus provides a therapeutic opportunity to selectively target antibody-driven autoimmune and inflammatory disorders mediated by the classical pathway while leaving the lectin and alternative pathways intact.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.6.1-3"></a>

###### Targeting of the small active fraction of circulating C1s

> “By selectively targeting only the active form of C1s, which drives disease pathology and constitutes only a small fraction of the total protein present in circulation, we aim to reduce the amount of drug required for a therapeutic effect.”
> “DNTH103 is designed to selectively target the active form of C1s, inhibiting only the classical pathway, while leaving the lectin and alternative pathways intact.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-2.1.2.6.1-4"></a>

###### Binding selectivity for active C1s over proC1s

> “High selectivity and potency >10,000-fold binding affinity for Active C1s versus proC1s Picomolar binding affinity”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="topic-2.1.2.6.1-5"></a>

###### Upstream blockade of C3a, C3b, and membrane attack complex formation

> “Selectively targets start of the classical complement pathway, thereby blocking MAC formation and C3a/C3b pro-inflammatory complement components”
> “No impact on lectin or alternative pathways, potentially preserving complement- mediated defense against encapsulated bacteria infection”
> “C2 inhibitors block both the classical and lectin pathways”
> “C5 inhibitors impact all three complement pathways, including classical, lectin and alternative”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.6.1-6"></a>

###### Company description of the mechanism: latest statement

> “Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target.”
> “Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Classical pathway inhibition in healthy volunteers: phase 1

> “DNTH103 has demonstrated deep and sustained complement inhibition in healthy volunteers DNTH103 demonstrated a ~60-day half-life and IC90 of 87 µg/mL”
> “Safety, PK, and PD measured by percent classical pathway inhibition quantified in each cohort”
> “DNTH103 Phase 1 data confirms potent inhibition of the classical pathway as a Q2W S.C. injection ~60-day half-life IC90 calculated at 87 µg/mL”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="topic-2.1.2.6.2-2"></a>

###### In vitro affinity and potency compared with riliprubart

| Assay | DNTH103 | Riliprubart |
| --- | --- | --- |
| Binding affinity to human active C1s, KD (KinExa) | “9pM” | “75pM” |
| Binding affinity to human active C1s, KD (SPR) | “8pM” | “35pM” |
| C4 cleavage by human active C1s, IC90 (nM) | “0.47” | “3.69” |
| Wieslab classical pathway assay in human serum, IC90 (μg/mL) | “0.45” | “5.4” |
| CH50 assay of RBC lysis in human serum, IC90 (μg/mL) | “98” | “668” |
| Liposome lysis in human serum, IC90 (μg/mL) | “14.7” | “39.8” |

Source: [Katzberg et al. (2024)](https://investor.dianthustx.com/static-files/f8df567c-6c87-4c24-9195-34850953731f)

> “DNTH103 consistently outperforms riliprubart* in affinity and potency when compared head-to-head across multiple in vitro experiments”
> “Riliprubart is produced using sequence from patent WO2018071676A1”

Source: [Katzberg et al. (2024)](https://investor.dianthustx.com/static-files/f8df567c-6c87-4c24-9195-34850953731f)

<a id="topic-2.1.2.6.2-3"></a>

###### Restoration of nerve conduction velocity in an in vitro CIDP model

> “Serum from three CIDP patients was evaluated in a validated commercially available in vitro CIDP model”
> “Endpoint: DNTH103 was evaluated at two doses, results were characterized relative to baseline conduction velocity determined in sera from healthy volunteers (n=3)”
> “DNTH103 completely restores conduction velocity across the axons of human motor neurons in the presence of pathological autoantibodies from CIDP patient sera”
> “Three sera were positive for NF155 (autoantibody test panel: NF155, NF186, CNTN1, CASPR1)”

Source: [Katzberg et al. (2024)](https://investor.dianthustx.com/static-files/f8df567c-6c87-4c24-9195-34850953731f)

<a id="topic-2.1.2.6.2-4"></a>

###### Pharmacokinetic, pharmacodynamic, and immunogenicity assessments in CAPTIVATE

> “Safety and tolerability, including adverse events • Pharmacokinetics and pharmacodynamics • Immunogenicity of claseprubart • Assess effect of claseprubart on biomarkers of disease activity”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Fc engineering for half-life extension

> “Claseprubart is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic”
> “profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “YTE, 3 amino acid substitutions at positions 249, 251 and 253 in the IgG4 heavy chain constant region (M249Y/S251T/T253E)”

Source: [Gokhale et al. (2024)](https://investor.dianthustx.com/static-files/385658f0-0e93-4df3-8b31-a1c0077c9024)

<a id="topic-2.1.2.6.3-2"></a>

###### Phase 1 study design for pharmacokinetic assessment

> “We evaluated DNTH103 in a first-in-human Phase 1 single ascending dose”
> “clinical trial in New Zealand to explore the safety, tolerability, PK, and pharmacodynamics”
> “We reported data from 60 healthy volunteers that have been dosed across eight cohorts, including six SAD cohorts: 1mg/kg intravenous”
> “10mg/kg I.V., 30mg/kg I.V., 50mg/kg I.V., 300mg S.C. and 600mg S.C.; and two MAD cohorts: 300mg S.C. and 600mg. S.C.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-2.1.2.6.3-3"></a>

###### Elimination half-life of approximately 60 days

> “Additionally, based on data from this clinical trial, DNTH103 has a half-life of approximately 60 days.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

> “The top-line data confirmed its approximately 60-day half-life and highly potent classical pathway inhibition with Q2W S.C. dosing of 300mg/2mL surpassing the serum concentration required to surpass 90% classical pathway inhibition in a hemolytic assay estimated to be 87ug/mL”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “Highly potent, ~8-week half-life, Classical Pathway (CP) inhibitor targeting active C1s”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.6.3-4"></a>

###### Dose proportionality and accumulation in phase 1

> “I.V. SAD: Linear PK with Exposure Proportional Across Doses S.C. MAD: Strong Accumulation with Q2W Dosing PK/PD: Analysis Demonstrates IC90 of 87 µg/mL Data comprised of 60 HVs from 8 cohorts”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="topic-2.1.2.6.3-5"></a>

###### Simulated steady-state exposure relative to the IC90

> “With these data, we conducted a PK simulation that demonstrates the steady state serum concentration of DNTH103, when dosed 300mg S.C. Q2W following an initial I.V. loading dose, exceeds the serum concentration required to surpass 90% classical pathway inhibition in a hemolytic assay”
> “estimated to be 87ug/mL. We believe, based on published scientific literature related to other complement therapies, that the IC90 will be sufficient to achieve clinical activity in patients with gMG, CIDP, and MMN.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

> “Simulation using data from 60 healthy volunteers dosed across multiple cohorts demonstrates potent inhibition with infrequent S.C. dosing IC90 – 87 µg/mL Day 0: 15mg/kg I.V. Starting Day 7: 300mg S.C. Q2W Dosing Modeled”
> “300mg and 600mg S.C. Q2W dosing surpasses IC90 (87 µg/mL) and IC95 (149 µg/mL), respectively”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="topic-2.1.2.6.3-6"></a>

###### Observed steady-state concentration with 300 mg every 2 weeks: phase 2

> “PK of ~65 μg/mL at week 4 after only two 600mg/4mL doses is substantially lower than steady state seen with 300mg/2mL dosing of ~100-120 μg/mL”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA written feedback on antinuclear antibody testing and the autoimmune risk description

> “In addition, in the first quarter of 2026, the Company proposed to the Food & Drug Administration”
> “the following changes to screening criteria and required routine labs, and the description of the hypothetical autoimmune safety risk across claseprubart clinical trials, based on patient experience to date and scientific consensus from published data:”
> “a common reason for screen failure across all three claseprubart programs; 2. Removal of routine ANA testing during claseprubart clinical trials; and 3. Reclassification of the hypothetical risk of systemic lupus erythematosus”
> “a side effect in several classes of widely used medications characterized by the reversal of symptoms upon discontinuation of the precipitating medication. In March 2026, the Company received written feedback from FDA agreeing to all three of these proposals for all ongoing and planned future claseprubart trials. Of note there have been no cases of either SLE or DIL to date in any claseprubart program.”

Source: [Dianthus Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm)

<a id="topic-2.1.2.7.1-2"></a>

###### Antinuclear antibody seroconversion: phase 2 randomized period

| Measure | Placebo (N=22) | Claseprubart 300mg/2mL Q2W (N=21) | Claseprubart 600mg/4mL Q2W (N=22) |
| --- | --- | --- | --- |
| Newly positive for anti-nuclear antibodies (ANA) | “0 (0%)” | “1 (5.9%)” | “8 (36.4%)” |
| Rashes | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Arthralgia | “1 (4.5%)” | “1 (4.8%)” | “0 (0%)” |

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Represents participants who were ANA negative at baseline and tested positive at ≥1:320 at any point during RCT (percentages calculated from n=17 for 300mg arm and n=22 for 600mg arm). An ANA titer of ≥1:320 was an exclusion criterion for the clinical trial protocol. At end of RCT (Week 13), 2 of the 8 patients in 600mg arm tested negative for ANA, 2 of the 8 patients in 600mg arm remained positive but at <1:320.”
> “Drug-Induced Lupus (DIL) is an autoimmune syndrome triggered by specific medications, such as statins, TNF-alpha inhibitors, and ACE inhibitors/beta-blockers. A key distinguishing feature of DIL is its reversibility, as symptoms typically resolve once the offending medication is withdrawn.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.7.1-3"></a>

###### Antinuclear antibody testing removed from current trial protocols

> “No ANA screening exclusion criteria or routine ANA testing during the RCT or OLE”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.7.1-4"></a>

###### Infection risk: rationale for sparing the lectin and alternative pathways

> “As a result, DNTH103 may have a reduced risk of infections from encapsulated bacteria when compared to C5 terminal inhibitors, thus potentially avoiding an FDA Boxed Warning and associated Risk Evaluation and Mitigation Strategy”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-2.1.2.7.1-5"></a>

###### Infection risk: in vitro meningococcal killing assay

> “DNTH103 in vitro study demonstrates lower risk of Neisseria meningitidis infections”
> “N. meningitidis bacterial killing is unaffected despite inhibition of the classical pathway”
> “In this assay, DNTH103 maintained bacterial killing, potentially leading to a decreased risk of infection vs. anti-C5 antibody*”

Source: [Vissing et al. (2024)](https://investor.dianthustx.com/static-files/0ec7e0cd-6d44-419f-b020-01f204c56da3)

<a id="topic-2.1.2.7.1-6"></a>

###### Infection and autoimmune events reported in clinical trials to date

> “In addition, claseprubart was generally well tolerated with no related serious infections, no clinical symptoms of DIL, no related SAEs or discontinuations due to safety.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “Safety and tolerability of claseprubart in the OLE was consistent with the RCT, including no meningococcal infections.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-2.1.2.7.1-7"></a>

###### Trial precautions: vaccination, complement deficiency, meningococcal history, and lupus

> “Documented vaccinations against encapsulated bacteria in accordance with local requirements and based on vaccine availability”
> “Known complement deficiency Prior history (at any time) of N. meningitidis infection”
> “Diagnosis of systemic lupus erythematosus (SLE) or family history (defined as a parent, sibling, or child) of SLE”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.7.1-8"></a>

###### Extended half-life and duration of adverse effects

> “In addition, a half-life extension could prolong the duration of undesirable side effects, which could also inhibit market acceptance.”
> “An extended half-life may make it more difficult for patients to change treatments and there is a perception that half-life extension could exacerbate side effects, each of which may adversely affect our ability to gain market acceptance.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Age ranges studied in claseprubart trials

> “Ages Eligible for Study 18 Years to 75 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.8-2"></a>

###### Body weight ranges studied

> “Weight range between 40 kilograms (kg) and 120 kg.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.8-3"></a>

###### Pregnancy, lactation, renal function, and hepatic function: phase 1 exclusions

> “Estimated creatinine clearance (CrCl) < 60 mL/min during Screening or at check-in day (Day -1) using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.”
> “Liver test results during Screening or at check-in day (Day 1) that are elevated more than 1.5-fold above the ULN for gamma glutamyl transferase, bilirubin (total), aspartate aminotransferase (AST) or alanine aminotransferase (ALT), unless a diagnosis of Gilbert syndrome.”
> “For women of childbearing potential (WOCBP), a positive serum pregnancy test at the Screening visit or a positive urine pregnancy test (with confirmatory serum pregnancy test) at check-in (Day -1).”
> “Females who are breastfeeding or planning to breast feed at any time during the study.”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Claseprubart

<a id="topic-2.1.2.9.1-1"></a>

###### Intravenous immunoglobulin: phase 1 Part C pharmacokinetic study

> “Part A and Part B have already been registered and this registration of Part C will be evaluating DNTH103 PK following administration of human normal immunoglobulin (Ig)G. Part C will be open label and will not be placebo controlled.”
> “Single dose DNTH103, administered on Day 1 after administration of Privigen NZ solution for IV infusion on Days -8 and -7”
> “IV7, 0.5 g/kg of body weight per day for 2 consecutive days (total dose: 1 g/kg)”
> “Investigational Product: DNTH103 IV infusion, 1 week after Privigen NZ solution: • IV7, 10 mg/kg Investigational Product: DNTH103 SC injection, 1 week after Privigen NZ solution: • IV7, 600 mg”
> “To evaluate the pharmacokinetics (PK) of DNTH103 when administered IV following administration of IgG, as a single dose in healthy adult volunteers.”
> “Recruitment status Completed”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-2.1.2.9.1-2"></a>

###### Immunoglobulin switch and prior complement or anti-CD20 therapy: CAPTIVATE

> “For patients on IV or SC Ig, the last dose for both must occur 1 week prior to Day 1 of Part A. Patients who received complement inhibitors or anti-CD20 treatments within the previous 6 months are not eligible.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Claseprubart on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### CAPTIVATE regimen by study part

> “Claseprubart intravenous (IV) loading dose on Day 1. Claseprubart subcutaneous (SC) once every 2 weeks for up to 13 weeks.”
> “Experimental: Claseprubart (Part B) Claseprubart SC once every 2 weeks for up to 52 weeks.”
> “Placebo Comparator: Placebo (Part B) Placebo SC once every 2 weeks for up to 52 weeks.”
> “Experimental: Claseprubart (Optional OLE) Claseprubart SC once every 2 weeks for up to 104 weeks.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.10.1-2"></a>

###### Part A and Part B dose: 300 mg subcutaneously every 2 weeks

> “Part A is a 13-week open-label period in which patients are administered SC 300mg claseprubart Q2W for 13 weeks following an IV loading dose (Figure 2).”
> “Patients who responded (≥1 point decrease in INCAT score) were eligible for Part B and randomized to receive 300mg claseprubart SC Q2W or placebo”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-2.1.2.10.1-3"></a>

###### Removal of the 600 mg Part B arm after the interim responder analysis

> “Maintain the claseprubart 300mg/2mL S.C. Q2W dose in Part A; • Engage with regulators to remove the claseprubart 600mg/4mL S.C. Q2W arm from Part B;”

Source: [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm)

> “Dosing: I.V. Loading Dose followed by 300mg/2mL S.C. Q2W in Part A; followed by 300mg/2mL or placebo in Part B”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.10.1-4"></a>

###### Switching from immunoglobulin and corticosteroids

> “Last dose of Ig and tapering of steroids completed 1 week prior to switching to claseprubart”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Intravenous loading dose followed by subcutaneous injection

> “Claseprubart intravenous (IV) loading dose on Day 1. Claseprubart subcutaneous (SC) once every 2 weeks for up to 13 weeks.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.10.2-2"></a>

###### Prefilled syringe used in the phase 3 EMERGE trial

> “IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart Q2W starting at Week 1 (Day 8). Drug: Claseprubart IV loading dose on Day 1 Other Names: DNTH103 Combination Product: Claseprubart Prefilled syringe containing claseprubart for SC administration”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.10.2-3"></a>

###### Target presentation: 300 mg/2 mL self-administered autoinjector

> “Targeting convenience of a single, self-administered S.C. 300mg/2mL autoinjector dosed every 2 or 4 weeks”
> “Autoinjector for claseprubart administration is anticipated to be SHL Medical’s Molly technology, patented or patent pending in the US, China, India, Japan, Korea, Taiwan and at the European Patent Office.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “<10-Second Autoinjector Targeting No Boxed Warning or REMS Self-Administered At Home or On-the-Go”

Source: [Dianthus Therapeutics presentation (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-ex99_1.htm)

<a id="topic-2.1.2.10.2-4"></a>

###### Formulation concentration and viscosity

> “Low volume S.C. delivery Successful manufacturing of 150mg/mL formulation Low viscosity Favorable stability profile DNTH103 Target Product Profile S.C. self-administration 300mg in a 2mL pre-filled auto-injector suitable for convenient, self-administration”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Contract manufacturing: WuXi Biologics

> “We do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We contract with third parties for the manufacture and distribution of our product candidates.”
> “On March 22, 2021, we entered into a biologics master services agreement”
> “manufacturing and testing for claseprubart, as well as potential future candidates, on a work order basis.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-2"></a>

###### Cell line license and royalty on commercial supply from another manufacturer

> “Under the Cell Line License Agreement, we received a non-exclusive, worldwide, sublicensable license to certain of WuXi Biologics’ know-how, cell line, biological materials and media and feeds to make, have made, use, sell and import certain drug products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement”
> “Additionally, if we manufacture all of our commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, we are required to make royalty payments to WuXi Biologics in an amount equal to a fraction of a single digit percentage of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-3"></a>

###### Supply chain contingency: BIOSECURE Act

> “we are strengthening our supply chain in the event that WuXi Biologics or one of our other manufacturers is impacted by the BIOSECURE Act or any similar legislation.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

###### Commercialization plans

> “Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs.”
> “Given the company’s stage of development, we currently do not have a commercial organization for the marketing, sales and distribution of pharmaceutical products.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-5"></a>

###### Greater China license: Tenacia Biotechnology

> “We are currently a party to a license agreement with Tenacia Biotechnology (Hong Kong) Co., Limited”
> “for claseprubart, pursuant to which Tenacia has development and commercialization rights in the People’s Republic of China, including Hong Kong, Macau, and Taiwan”
> “On October 21, 2024, Zenas assigned the Zenas License Agreement to its affiliated entity, Zenas BioPharma (HK) Limited”
> “a $2.5 million upfront payment, which was paid to us by Tenacia in October 2024 upon execution of the Tenacia License Agreement; (ii) reimbursement of a portion of certain clinical costs; (iii) development milestones totaling up to $15.0 million; and (iv) royalties on net sales ranging from the mid-single digits to the low teen percentages.”
> “Tenacia is also responsible for paying local development costs in Greater China and a portion of central development costs based on the number of patients enrolled from China in our global Phase 3 studies.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-6"></a>

###### Autoinjector device: SHL Medical Molly technology

> “Autoinjector for claseprubart administration is anticipated to be SHL Medical’s Molly technology, patented or patent pending in the US, China, India, Japan, Korea, Taiwan and at the European Patent Office.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.11-7"></a>

###### Patent protection

> “Patents issuing from these applications covering claseprubart would be expected to expire no earlier than 2043, subject to any disclaimers or extensions.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “claseprubart IP protection expected through at least 2043, excluding extensions”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Prior and current CIDP treatment permitted at entry to the phase 3 trial

> “Must fulfill one of the following treatment conditions for CIDP:”
> “Currently treated with and responded to immunoglobulin (Ig) (intravenous immunoglobulin [IVIg] or subcutaneous immunoglobulin [SCIg]) alone or Ig (IVIg or SCIg) plus oral corticosteroids, or previously treated with and responded to, but are no longer being treated with (eg, lost access to), a maintenance regimen of Ig (IVIg or SCIg) alone or Ig (IVIg or SCIg) plus oral corticosteroids.”
> “Currently treated with and responded to oral corticosteroids alone or oral corticosteroids in combination with azathioprine or mycophenolate mofetil.”
> “Treatment naïve with no history of prior treatment for CIDP.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.12-2"></a>

###### Corticosteroids, immunosuppressants, and immunoglobulin during the phase 3 trial

> “If applicable, oral corticosteroids (after tapering) and allowed immunosuppressants are continued in Parts A and B.”
> “For patients on IV or SC Ig, the last dose for both must occur 1 week prior to Day 1 of Part A.”
> “Patients who received complement inhibitors or anti-CD20 treatments within the previous 6 months are not eligible.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

> “Last dose of Ig and tapering of steroids completed 1 week prior to switching to claseprubart”
> “No requirement for washout or deterioration”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="topic-2.1.2.12-3"></a>

###### Rescue therapy and return to standard of care in the phase 3 trial

> “Additionally, patients who have a relapse in Part B (increase of ≥1 point in adjusted INCAT score) are also eligible for the OLE, including those who received Ig, corticosteroid, or PLEX rescue therapy.”
> “Patients can resume standard of care treatment for CIDP per the investigator’s judgment.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-2.1.2.12-4"></a>

###### Required vaccination against encapsulated bacteria in the phase 3 trial

> “Documented vaccinations against encapsulated bacteria in accordance with local requirements and vaccine availability.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.12-5"></a>

###### Treatment at study entry: interim analysis of the first 40 participants

> “Most patients presented with typical CIDP with a mean (SD) time from diagnosis of 4.2 (6.1) years and were receiving immunoglobulins or oral corticosteroids at study entry (Table 1).”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

| Prior treatment group | Claseprubart 300 mg every 2 weeks (N=40), n (%) |
| --- | --- |
| Standard of care treated | “27 (67.5)” |
| Immunoglobulin | “19 (47.5)” |
| Oral corticosteroids | “8 (20.0)” |
| Standard of care refractory | “9 (22.5)” |
| Treatment naive | “4 (10.0)” |

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Claseprubart on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Claseprubart: mechanism, route, dosing interval, and approval status

| Attribute | Quoted text |
| --- | --- |
| Approval status | “Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.” |
| Mechanism of action | “potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein” |
| Route and dosing interval | “Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks.” |
| Regimen in the CIDP phase 3 trial | “The Phase 3 CAPTIVATE trial of claseprubart 300mg/2mL S.C. Q2W” |

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

> “Claseprubart intravenous (IV) loading dose on Day 1.”
> “Claseprubart subcutaneous (SC) once every 2 weeks for up to 13 weeks.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.14-2"></a>

###### Immune globulin intravenous 10%: Gamunex-C

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “GAMUNEX-C FlexBag, [immune globulin injection (human), 10%, caprylate/chromatography purified] for intravenous use.” |
| CIDP indication | “GAMUNEX-C FlexBag is indicated for the treatment of CIDP in adults to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.” |
| Mechanism of action in CIDP | “The precise mechanism of action in CIDP has not been fully elucidated.” |
| CIDP dosing and interval | “GAMUNEX-C FlexBag may be administered as a maintenance infusion of 1 g/kg (10 mL/kg) administered over 1 day or divided into two doses of 0.5 g/kg (5 mL/kg) given on two consecutive days, every 3 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2003” |

Source: [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download)

<a id="topic-2.1.2.14-3"></a>

###### Immune globulin intravenous 10%: Privigen

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “PRIVIGEN, Immune Globulin Intravenous (Human), 10% Liquid” |
| CIDP indication | “Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults (1.3)” |
| Limitation of use in CIDP | “PRIVIGEN maintenance therapy in CIDP has not been studied beyond 6 months.” |
| Mechanism of action | “The mechanism of action has not been fully elucidated” |
| CIDP dosing and interval | “Maintenance dose: 1 g/kg (10 mL/kg) administered in 1 to 2 infusions on consecutive days, every 3 weeks” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2007” |

Source: [Privigen prescribing information (2025)](https://www.fda.gov/media/83304/download)

<a id="topic-2.1.2.14-4"></a>

###### Immune globulin intravenous 10%: Panzyga

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “PANZYGA, (immune globulin intravenous, human - ifas) 10% Liquid Preparation” |
| CIDP indication | “Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults” |
| Mechanism of action in CIDP | “The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated.” |
| CIDP dosing and interval | “Maintenance dose: 1-2 g/kg (10-20 mL/kg) every 3 weeks divided in 2 doses given over 2 consecutive days” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2018” |

Source: [Panzyga prescribing information (2021)](https://www.fda.gov/media/115397/download)

<a id="topic-2.1.2.14-5"></a>

###### Immune globulin intravenous 10%: Gammagard Liquid

| Attribute | Prescribing information |
| --- | --- |
| Product | “GAMMAGARD LIQUID is an immune globulin infusion (human)” |
| CIDP indication | “Therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).” |
| Limitation of use in CIDP | “Safety and effectiveness of GAMMAGARD LIQUID has not been studied in immunoglobulin-naïve patients with CIDP.” |
| Route in CIDP | “CIDP: Intravenous (IV)” |
| Mechanism of action in CIDP | “The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated but may include immunomodulatory effects.” |
| CIDP dosing and interval | “Maintenance dose is 1 g/kg in divided doses over 1 to 4 consecutive days, every 3 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2005” |

Source: [Gammagard Liquid prescribing information (2024)](https://www.fda.gov/media/191699/download)

<a id="topic-2.1.2.14-6"></a>

###### Immune globulin subcutaneous 20%: Hizentra

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “HIZENTRA is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Liquid” |
| CIDP indication | “HIZENTRA is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.” |
| Mechanism of action | “The mechanism of action has not been fully elucidated, but may include immunomodulatory effects.” |
| CIDP dosing | “Recommended subcutaneous dose is 0.2 g/kg (1 mL/kg) body weight per week.” |
| CIDP dosing interval | “CIDP: Administer weekly.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2010” |

Source: [Hizentra prescribing information (2021)](https://www.fda.gov/media/78466/download)

<a id="topic-2.1.2.14-7"></a>

###### Immune globulin 10% with recombinant human hyaluronidase: HyQvia

| Attribute | Prescribing information |
| --- | --- |
| Product | “HYQVIA is an Immune Globulin Infusion (Human), 10% with a Recombinant Human Hyaluronidase (rHuPH20)” |
| CIDP indication | “Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)” |
| Route | “For subcutaneous use only” |
| Mechanism of action in CIDP | “The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated but may include immunomodulatory effects.” |
| Role of hyaluronidase | “The rHuPH20 of HYQVIA increases permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan.” |
| CIDP dosing and interval | “The starting dose and dosing frequency of HYQVIA is the same as the patient’s previous IGIV treatment. The typical dosing interval range in the clinical trial for HYQVIA was 2 to 4 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2014” |

Source: [HyQvia prescribing information (2026)](https://www.fda.gov/media/89844/download)

<a id="topic-2.1.2.14-8"></a>

###### Neonatal Fc receptor blocker: Vyvgart Hytrulo

| Attribute | Prescribing information |
| --- | --- |
| Product | “VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase” |
| CIDP indication | “chronic inflammatory demyelinating polyneuropathy (CIDP)” |
| Mechanism of action | “Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Route | “VYVGART HYTRULO is for subcutaneous use only.” |
| Self-administration | “Prefilled syringe can be administered by patients and/or caregivers.” |
| CIDP dosing interval | “Administer as once weekly injections.” |
| CIDP dose, prefilled syringe | “Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over approximately 20 to 30 seconds.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

> “In June 2024, Vyvgart Hytrulo, marketed by argenx, was approved for the treatment of CIDP.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.14-9"></a>

###### Investigational C1s inhibitor riliprubart: phase 3 status

> “Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped.”
> “This decision follows an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study is unlikely to provide sufficient efficacy.”
> “The continuation of other ongoing studies with riliprubart, including the VITALIZE phase 3 study (clinical study identifier: NCT06290141) in IVIg-treated patients with CIDP, will be evaluated accordingly.”
> “Riliprubart (SAR445088, BIVV020) is an IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system.”

Source: [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444)

<a id="topic-2.1.2.14-10"></a>

###### Investigational C2 inhibitor empasiprubart: phase 3 status

> “empasiprubart is a differentiated therapeutic mAb targeting C2”
> “argenx is advancing two Phase 3 clinical trials of empasiprubart in CIDP: EMVIGORATE and EMNERGIZE.”
> “Topline results from both EMVIGORATE and EMNERGIZE are expected in the second half of 2027.”
> “In addition to an IV formulation”

Source: [argenx annual report (2026)](https://reports.argenx.com/2025/argenx-group/our-products-and-product-candidates/empasiprubart-development.html)

<a id="topic-2.1.2.14-11"></a>

###### Investigational C2 inhibitor empasiprubart: placebo-controlled phase 3 trial registration (EMNERGIZE)

> “A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy”
> “The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).”
> “Reduction of ≥1 point compared with baseline in aINCAT score at week 24”
> “Study Start (Actual) 2025-09-16”
> “Primary Completion (Estimated) 2027-10-07”
> “Enrollment (Estimated) 160”

Source: [ClinicalTrials.gov NCT07091630](https://clinicaltrials.gov/study/NCT07091630)

<a id="topic-2.1.2.14-12"></a>

###### Investigational C2 inhibitor empasiprubart: head-to-head phase 3 trial registration against intravenous immunoglobulin (EMVIGORATE)

> “A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy”
> “This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).”
> “Study Start (Actual) 2025-08-22”
> “Primary Completion (Estimated) 2027-09”
> “Enrollment (Estimated) 218”

Source: [ClinicalTrials.gov NCT06920004](https://clinicaltrials.gov/study/NCT06920004)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Disease definition: immune-mediated demyelinating disorder of the peripheral nerves and nerve roots

> “Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disorder of the peripheral nerves and nerve roots causing limb weakness and sensory deficits”
> “CIDP is considered an immune-mediated disorder although the pathogenesis and aetiology of CIDP remain elusive”

Source: [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/)

> “Chronic inflammatory demyelinating polyradiculopathy (CIDP) is a symmetric, motor greater than sensory, proximal and distal demyelinating peripheral neuropathy with a slowly progressive or relapsing course.”

Source: [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)

> “CIDP is caused by primary immune‐mediated demyelination and secondary axonal damage in the peripheral nervous system, resulting in progressive muscle weakness and sensory impairment that led to significant disability”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.1-2"></a>

###### Typical CIDP and CIDP variants in the EAN/PNS 2021 guideline

> “Typical CIDP and CIDP variants were distinguished. The previous term "atypical CIDP" was replaced by "CIDP variants" because these are well characterized entities (multifocal, focal, distal, motor, or sensory CIDP).”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

> “Typical CIDP manifests as symmetrical sensorimotor neuropathy with proximal and distal limb involvement with absent or reduced tendon reflexes. Weakness must be more or less symmetric in all four limbs and the severity of proximal and distal weakness should be similar. Sensory disturbances are to be found in at least two limbs.”
> “The CIDP variants, which were formerly referred to as atypical CIDP variants,”
> “are specific clinical syndromes that share the same signs that are supportive of demyelination and respond to the same therapies and are therefore considered to be on the same disease spectrum as sensorimotor CIDP.”

Source: [van Doorn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10875175/)

<a id="topic-2.2.1.1-3"></a>

###### Distribution of clinical phenotypes in national cohorts

> “Typical CIDP was the most frequent subtype (52%), followed by distal (17%) and multifocal/focal CIDP (17%).”

Source: [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/)

> “We identified 106 patients with typical CIDP (29%), 62 distal CIDP (17%), 28 multifocal or focal CIDP (7%), four sensory CIDP (1%), 27 sensory‐predominant CIDP (7%), 10 motor CIDP (3%), and eight motor‐predominant CIDP (2%).”

Source: [De Lorenzo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11235819/)

> “Patients were diagnosed with typical CIDP (69.2%) and variant CIDP (30.8%).”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.1-4"></a>

###### Etiology: immune triggers and target antigens unidentified in most patients

> “Though the exact triggers are unclear, diverse immune mechanisms encompassing cellular and humoral pathways are implicated.”
> “However, the trigger(s) for the autoimmune response and the target antigen(s) involved remain elusive in most patients”
> “A systematic screening of antibodies revealed a diverse antibody repertoire in CIDP patients, including those against NF-155 (4.6%), CNTN1 (6.2%), Caspr1/CNTN1 complex (1.5%), P2 (1.6%), and anti-ganglioside antibodies (18.6%).”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.1-5"></a>

###### Risk factors: older age, male sex, and diabetes mellitus

> “The incidence rates increased with age for both sexes and were higher in males compared with females aged ≥55 years”
> “The finding that epidemiologic rates of CIDP were higher among males vs. females aged ≥55 years distinguishes CIDP from other autoimmune diseases, which are typically more prevalent in women across the lifespan”
> “The most common comorbidity was diabetes mellitus.”

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)

> “Only 1 of the 23 CIDP patients (4%) also had DM, whereas 14 of 115 age- and sex-matched controls (12%) had DM.”
> “Diabetes mellitus (DM) is unlikely to be a major risk covariate for CIDP, but we cannot exclude a small effect.”

Source: [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Chronic inflammatory demyelinating polyneuropathy

<a id="topic-2.2.1.2.1-1"></a>

###### United States: claims-based incidence, 2023

> “After adjusting for age and sex and extrapolating to the US population, the estimated incidence rate was 2.8 (95% CI 2.7–2.9) per 100,000 persons or approximately 9,238 patients diagnosed with CIDP in 2023.”
> “corresponding to a raw incidence rate of 2.2 (95% CI 2.0–2.3) per 100,000 persons in 2023”
> “Patients were identified as having CIDP if they had 2 or more claims containing ICD-10 codes for CIDP (G61.81) separated by 30 or more days”
> “In this analysis, the incidence estimate decreased and prevalence estimate increased compared to our 2019 analysis, for which we calculated an adjusted incidence rate of 3.6 per 100,000 persons per year”

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)

<a id="topic-2.2.1.2.1-2"></a>

###### United States: Olmsted County, Minnesota, population-based incidence, 1982 to 2001

> “To determine the incidence (1982–2001) and prevalence (on January 1, 2000) of CIDP in Olmsted County, Minnesota, and whether DM is more frequent in CIDP.”
> “The incidence of CIDP was 1.6/100,000/year.”

Source: [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)

<a id="topic-2.2.1.2.1-3"></a>

###### Global pooled incidence: systematic review and meta-analysis

> “The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21–0.53; I2 = 95.7%)”
> “Crude incidence rates varied between 0.15 and 0.70 cases per 100,000 person-years”
> “The pooled crude incidence rate for studies using the AAN criteria is 0.36 per 100,000 person-years (95% CI 0.30–0.44, I2 = 0.0%; prediction interval 0.30–0.44).”
> “In general, the reported crude incidence rates were higher in males than females (gender rate ratios varied between 1.5 and 4.0; Table 3).”

Source: [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/)

<a id="topic-2.2.1.2.1-4"></a>

###### South Korea: nationwide claims-based incidence, 2016 to 2020

> “The age-adjusted incidence rates were 0.22, 0.21, 0.23, 0.30, and 0.25 per 100,000 person-years in 2016, 2017, 2018, 2019, and 2020, respectively.”

Source: [Jung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10622719/)

<a id="topic-2.2.1.2.1-5"></a>

###### Iceland: population-based incidence, 1991 to 2011

> “The average annual incidence was 0.3/100,000 (95% CI 0.04-2.47).”

Source: [Hafsteinsdottir and Olafsson (2016)](https://pubmed.ncbi.nlm.nih.gov/27211228/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Chronic inflammatory demyelinating polyneuropathy

<a id="topic-2.2.1.2.2-1"></a>

###### United States: claims-based prevalence and estimated number of persons, 2023

> “The adjusted rate was 23.3 (95% CI 23.1–23.5) per 100,000 persons, which corresponds to an estimated 77,058 individuals living with CIDP in the USA in 2023.”
> “corresponding to a raw prevalence rate of 16.8 (95% CI 16.5–17.2) per 100,000 persons”
> “we calculated an adjusted incidence rate of 3.6 per 100,000 persons per year and an adjusted prevalence rate of 18.0 per 100,000 persons to estimate that 58,405 individuals were living with CIDP in the USA in 2019”
> “Furthermore, the medical claim codes used in this study may reflect suspected CIDP and may not represent a confirmed clinical diagnosis of CIDP.”

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)

<a id="topic-2.2.1.2.2-2"></a>

###### United States: Olmsted County, Minnesota, population-based prevalence, 2000

> “The prevalence was 8.9/100,000 persons on January 1, 2000.”

Source: [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)

<a id="topic-2.2.1.2.2-3"></a>

###### United States: accuracy of CIDP diagnosis codes in claims data

> “The PPV of the algorithm requiring at least one CIDP diagnosis code before IVIG use was 66.2% (95% confidence interval [CI], 58.0-74.3). The PPV improved to 71.2% (62.7-79.6) when requiring at least two CIDP codes before IVIG use. The PPV for patients with at least one CIDP code who met the European Academy of Neurology/Peripheral Nerve Society 2021 diagnostic criteria was 30.0% (22.1-37.9).”

Source: [Okonkwo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40025632/)

<a id="topic-2.2.1.2.2-4"></a>

###### Global pooled prevalence: systematic review and meta-analysis

> “the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58–4.39; I2 = 99.1%)”
> “The crude prevalence rate varied between 0.67 and 7.7 cases per 100,000 persons (Table 4).”
> “Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria.”

Source: [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/)

<a id="topic-2.2.1.2.2-5"></a>

###### Japan: nationwide survey prevalence

> “The primary survey showed that the estimated number of patients with CIDP was 4,180, with a prevalence of 3.3 per 100,000 persons.”
> “The male-to-female ratio was 1.5:1, and the median age at onset was 52 years.”

Source: [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/)

<a id="topic-2.2.1.2.2-6"></a>

###### South Korea: nationwide claims-based prevalence, 2020

> “The age-adjusted prevalence was estimated at 1.16 per 100,000 persons in 2020.”

Source: [Jung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10622719/)

<a id="topic-2.2.1.2.2-7"></a>

###### United States: patients identified among 6.5 million commercial health plan members, 2011

> “CIDP patients from 9 U.S. commercial health plans with claims in 2011 were identified from the Accordant Health Services claims database.”
> “From 6.5 million covered lives, 73 (56% men; mean age 47) met study entry criteria.”

Source: [Guptill et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24639235/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Disease course: progressive, monophasic, or relapsing-remitting

> “The clinical course was progressive in 6, monophasic in 7, and relapsing–remitting in 10.”

Source: [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)

> “The disease course was remitting-relapsing in 21% and chronic progressive or monophasic in 79%.”

Source: [Hafsteinsdottir and Olafsson (2016)](https://pubmed.ncbi.nlm.nih.gov/27211228/)

> “Among patients with CIDP, 78% had a progressive/relapsing course, 14% did not respond to first-line treatments, and 18% could not walk independently at the last visit.”

Source: [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/)

<a id="topic-2.2.1.3-2"></a>

###### Remission and long-term treatment dependence

> “The pooled rate of remission was 40.8% (95% CI, 30.6% to 51.8%).”

Source: [Al-Zuhairy and Jakobsen (2023)](https://pubmed.ncbi.nlm.nih.gov/36928889/)

> “The 51 participating patients had a median disease duration of 16 (interquartile range, 14-21) years. Twenty-seven patients (53%) had discontinued therapy and 46 walked independently.”

Source: [Al-Zuhairy et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31793666/)

> “Approximately 30% of patients can achieve a durable period of drug‐free remission at some point in their disease.”

Source: [Cook et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10098814/)

> “The clinical response to these treatments is usually only partial and transient.”

Source: [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/)

<a id="topic-2.2.1.3-3"></a>

###### Mortality: pooled case fatality rate across long-term outcome studies

> “The pooled case fatality rate was 3.3% (95% confidence interval [CI], 1.9% to 5.7%).”

Source: [Al-Zuhairy and Jakobsen (2023)](https://pubmed.ncbi.nlm.nih.gov/36928889/)

<a id="topic-2.2.1.3-4"></a>

###### Mortality compared with the general population: Iceland

> “The standardized mortality ratio for the 21-year study period was 0.9 (95% CI 0.3-2.2).”
> “Many had no or only limited disease progression over the years and mortality is not increased compared with the general population.”

Source: [Hafsteinsdottir and Olafsson (2016)](https://pubmed.ncbi.nlm.nih.gov/27211228/)

<a id="topic-2.2.1.3-5"></a>

###### Mortality in treated patients: Denmark

> “For a few patients long-term CIDP was associated with severe morbidity (6%) and even mortality (1%).”

Source: [Al-Zuhairy et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31793666/)

<a id="topic-2.2.1.3-6"></a>

###### In-hospital mortality and its predictors: South Korea

> “Furthermore, 129 (13.50%) patients were treated in an ICU, and 80 (8.40%) died while receiving treatment at a medical institution.”
> “Age and the Elixhauser Comorbidity Index were associated with the in-hospital mortality of patients with CIDP. Infection and cardiovascular disease (CVD) were also significantly associated with the in-hospital mortality of those patients.”

Source: [Jung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10622719/)

<a id="topic-2.2.1.3-7"></a>

###### Mortality in the United States

No evidence found.

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Cellular and humoral immune mechanisms leading to macrophage-mediated demyelination

> “The pathogenesis of CIDP involves a complex interplay of multiple aberrant immune responses, creating a pro-inflammatory environment, subsequently inflicting damage on the myelin sheath.”
> “Histopathological changes in CIDP include breakdown of the blood–nerve barrier (BNB), segmental demyelination near the nodes of Ranvier, interstitial edema, and endoneurial inflammatory cell infiltration, including lymphocytes and macrophages and varying degrees of admixed axonal damage”
> “The response to plasma exchange therapy indicates the important role of circulating factors in CIDP pathogenesis”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.4-2"></a>

###### Complement activation pathways: the classical pathway is initiated through the C1 complex

> “Complement activation occurs through three different pathways: classical (C1q), lectin (mannose-binding lectins or ficolin), and alternative (C3 autoactivation or properdin), which converge at C3, the most abundant complement protein found in the blood”
> “Subsequently, the effector proteins C3a, C3b, and C5a and the membrane attack complex (MAC, C5b-9) are generated for target cell lysis”
> “The complement system appears to play a role in promoting macrophage-mediated demyelination.”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

> “Riliprubart, also known as SAR445088, targets active C1s protein, a C1 complex serine protease, responsible for activating the classical complement pathway.”

Source: [Stascheit et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12449320/)

<a id="topic-2.2.1.4-3"></a>

###### Complement deposition in sural nerve biopsies

> “Overall, 94% (n = 52) revealed abnormal and prominent deposition of terminal complement complex C5b-9 on endoneurial capillaries.”
> “In contrast, there was no complement deposition in NDC nor DC.”

Source: [Stascheit et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12449320/)

> “C4d was deposited on the myelin sheaths in all patients with CIDP, with significantly higher density and intensity than in controls. C3c was detected in three of the nine patients with CIDP, while C5b-9 was not detected.”
> “The classical and/or lectin pathways are predominantly involved in CIDP pathogenesis.”

Source: [Murakami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456398/)

> “In an early study, sural nerve biopsy specimens from seven patients with chronic relapsing demyelinating polyneuropathy showed deposition of IgM in intraneural blood vessels in all patients and deposition of C3 in six of the seven patients.”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.4-4"></a>

###### Systemic complement activation in serum and cerebrospinal fluid

> “Serum levels of activated complement proteins—C3a, C4a, Ba, Bb, C5a, and the soluble terminal complement complex sC5b-9 (sTCC)—were significantly elevated in CIDP patients compared to healthy donors (HD)”
> “Notably, concentrations of complement proteins indicative for more proximal activation of the classical and lectin (C1q, C4a, C4) pathway as well as of the alternative pathway (Ba, Bb) were also strikingly increased in CIDP compared to both CMT and HD”
> “Among CIDP patients, those with active, unstable disease exhibited significantly higher levels of terminal complement components (C5a and sTCC) compared to patients with stable disease or in remission”

Source: [Stascheit et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12794542/)

> “A study compared serum and CSF levels of C5a and terminal complement complex (TCC) in 21 newly diagnosed, treatment-naïve CIDP patients, with that of 29 control patients with noninflammatory neurological diseases. CIDP patients had significantly higher mean serum and CSF levels of C5a and TCC than control patients”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.4-5"></a>

###### Classical pathway inhibition at C1s in a human cell-based model of demyelinating neuropathy

> “Patient autoantibody binding was sufficient to activate the classical complement pathway resulting in detection of C3b and C5b-9 deposits.”
> “TNT005 rescued the serum-induced complement deposition and functional deficits while treatment with an isotype control antibody had no rescue effect.”

Source: [Rumsey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9540753/)

> “A human CIDP model was created by treatment of Schwann cell and motoneuron cultures with CIDP patient-derived serum, which triggered classical complement pathway activation and, subsequently, the deposition of C3b and C5b-9. Furthermore, treatment with a test monoclonal antibody inhibitor of C1s, TNT005, resulted in abrogation of complement deposition and rescued the electrophysiological deficits”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.4-6"></a>

###### Complement-independent mechanisms in IgG4 paranodal antibody disease

> “It is noteworthy that almost all the antibodies to these paranodal antigens were IgG4, an IgG subclass that is non-complement fixing”
> “Nonetheless, some variants of these neuropathies harbor IgG1-3 subclass of antibodies with ability to fix complement and could potentially be candidates to complement inhibition”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

> “The IgG4 antibodies exert pathogenic effects on their targeted antigens by blocking enzymatic activity or disrupting protein–protein interactions affecting signal transduction pathways, but not by activating complement, binding to inhibitory FcγRIIb receptor or engaging in cross-linking of the targeted antigen with immune complex formation as the IgG1-IgG3 antibody subclasses do.”

Source: [Dalakas (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294117/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### EAN/PNS 2021 guideline: two levels of diagnostic certainty and supportive criteria

> “The levels of diagnostic certainty were reduced from three (definite, probable, possible CIDP) to only two (CIDP and possible CIDP), because the diagnostic accuracy of criteria for probable and definite CIDP did not significantly differ. Good Practice Points were formulated for supportive criteria and investigations to be considered to diagnose CIDP.”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

> “Some notable changes from the previous guideline include the removal of distinctions between “definite” and “probable” conduction blocks, consolidating them into a singular category of conduction blocks. Furthermore, tibial nerve conduction blocks are no longer included and the threshold for temporal dispersion in the tibial nerve has been adjusted to necessitate at least a 100% increase in CMAP duration. Sensory criteria have transitioned from being merely supportive to being integral to the electrodiagnostic criteria.”

Source: [van Doorn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10875175/)

<a id="topic-2.2.1.5-2"></a>

###### Diagnostic accuracy of the EAN/PNS 2021 criteria compared with the EFNS/PNS 2010 criteria

> “We included 339 patients and 339 matched controls. Sensitivity of the 2010 EFNS/PNS guideline was 92% when including possible CIDP and 91% for probable/definite CIDP, with specificities of 67% and 78%, respectively. For the 2021 EAN/PNS guideline, sensitivity was 94% when including possible CIDP and 83% for CIDP, with specificities of 66% and 86%, respectively. Differences were due to sensory criteria and changes in conduction block criteria. Unilateral NCS would miss 77 possible CIDP diagnoses.”

Source: [van Doorn et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13434837/)

<a id="topic-2.2.1.5-3"></a>

###### Misdiagnosis in the United States: referred patients who did not meet diagnostic criteria

> “Forty-seven percent of patients referred with a diagnosis of CIDP failed to meet minimal CIDP diagnostic requirements.”
> “CIDP misdiagnosis is common. Over-reliance on subjective patient-reported perception of treatment benefit, liberal electrophysiologic interpretation of demyelination, and placing an overstated importance on mild or moderate cytoalbuminologic dissociation are common diagnostic errors.”

Source: [Allen and Lewis (2015)](https://pubmed.ncbi.nlm.nih.gov/26180143/)

> “Thirty-nine of 86 patients were found not to have CIDP. Initial electrodiagnostic data quality was generally acceptable, but initial electrodiagnostic conclusions were confirmed in only 45% of misdiagnosed studies.”

Source: [Allen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29053880/)

<a id="topic-2.2.1.5-4"></a>

###### Overdiagnosis and underdiagnosis at a European referral center

> “A referral diagnosis of CIDP was revised in 32% of patients (31/96; overdiagnosis). Of 81 patients diagnosed with CIDP, 16 (20%) were referred with another diagnosis (underdiagnosis).”
> “Diagnostic pitfalls include lack of attention to proximal muscle weakness as a diagnostic hallmark of CIDP, insufficient recognition of clinical atypical phenotypes, overreliance on CSF protein levels, misinterpretation of nerve conduction studies and poor adherence to electrodiagnostic criteria, and failure to exclude other causes of polyneuropathy.”

Source: [Broers et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8252611/)

<a id="topic-2.2.1.5-5"></a>

###### Initial misdiagnosis and diagnostic delay in a multinational survey

> “Overall, initial misdiagnosis occurred in 37.2% of patients, with a median (interquartile range) diagnostic delay of 6.0 (3.0–12.0) months.”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Motor symptoms: symmetric proximal and distal limb weakness

> “At initial admission, the most common symptoms were weakness (100% of typical CIDP, 91% of CIDP variants), sensory disturbances (97% of typical CIDP, 93% of CIDP variants), and/or ataxia (both 56%).”

Source: [Quint et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11377626/)

> “The following two commonly reported symptoms had larger ranges between regions, with distal muscle weakness ranging from 42.3% in the US to 75.7% in Japan, and peripheral tingling ranging from 21.7% in China to 64.4% in Europe”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.6-2"></a>

###### Sensory symptoms: numbness, tingling, and sensory ataxia

> “For symptoms experienced as an overall cohort, peripheral numbness was the most commonly reported at 70.5%, ranging from 67.4% in the US to 79.6% in Japan.”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

> “CIDP manifests typically as an insidious onset of weakness, hypo- or areflexia, numbness, paresthesia, and sensory ataxia with a progressive or relapsing–remitting pattern”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.6-3"></a>

###### Neurological signs: reduced or absent tendon reflexes

> “In both typical CIDP and CIDP variants, most patients (72% in typical and 60% in CIDP variants) exhibited areflexia in at least one muscle tendon reflex.”

Source: [Quint et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11377626/)

<a id="topic-2.2.1.6-4"></a>

###### Pain: neuropathic pain during the disease course

> “The pooled estimate of the prevalence of pain at any point within the course of CIDP was 46% (95% CI 36–57%).”

Source: [Michaelides et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6857093/)

<a id="topic-2.2.1.6-5"></a>

###### Movement symptoms: tremor and myoclonus

> “Of the 124 included CIDP patients, 86 patients (69%, 95% CI 61 to 77%) currently had clinically tremulous movements (CTM), mainly consisting of tremor but also of myoclonus or both. Lifetime prevalence was 76% (95% CI 68 to 83%).”
> “CTM were associated with CIDP-related and tremor-related disability and upper arm sensory impairment.”

Source: [Pallada et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13691695/)

<a id="topic-2.2.1.6-6"></a>

###### Fatigue

> “For all patients, the mean (SD) FACIT fatigue score was 35.0 (11.1). The majority of patients (52.7%) had scores between 36 and 51. Around one in ten (10.6%) scored between 0 and 19, indicative of severe fatigue”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.6-7"></a>

###### Autonomic symptoms: sudomotor, cardiovagal, gastrointestinal, and genitourinary dysfunction

> “Autonomic symptoms were uncommon, mainly gastrointestinal (9/47; 19%) and genitourinary (8/47; 17%). Autonomic deficits (CASS ≥1) were frequent (22/47; 47%) but very mild (CASS, 0.8 ± 0.9; CASS ≤3, all cases). Deficits were predominantly sudomotor (16/47; 34%) and cardiovagal (10/47; 21%) with relative adrenergic sparing (4/47; 9%).”

Source: [Figueroa et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3306161/)

> “Thirty-four (89%) patients had features of autonomic dysfunction. Thirty-three (86%) patients had cardiovagal dysfunction, 21 (55%) had adrenergic dysfunction, and 24 (63%) had sudomotor dysfunction. Autonomic dysfunction was mild to moderate in the majority (86%).”

Source: [Pasangulapati et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5586124/)

<a id="topic-2.2.1.6-8"></a>

###### Cranial nerve involvement in the multifocal variant

> “It predominantly affects the upper limbs, although lower limbs can be affected as well, while cranial nerve deficits are more common in this phenotype.”

Source: [van Doorn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10875175/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Long-term disability and loss of ambulation

> “The pooled fraction of nonambulatory patients was 8.2% (95% CI, 5.7% to 11.6%) and, overall, 47.1% (95% CI, 39.5% to 54.9%) of CIDP patients had a good outcome without disability.”

Source: [Al-Zuhairy and Jakobsen (2023)](https://pubmed.ncbi.nlm.nih.gov/36928889/)

> “Disability and isokinetic strength were impaired by 17% and 20%, respectively, as compared with matched control subjects.”

Source: [Al-Zuhairy et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31793666/)

> “Among the subtypes, typical CIDP had the most severe disability before treatment (44% of patients could not walk independently).”

Source: [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/)

<a id="topic-2.2.1.7-2"></a>

###### Use of mobility aids

> “Overall, 47.3% of patients with CIDP (ranging from 41.7% in Japan and 50.0% in China) were recorded to use mobility aids at the time of data collection. Across all regions, a cane/walking stick was used by 35.3% of patients, followed by the wheeled walker (8.0%), walking frame, and/or manual wheelchair (both 4.9%)”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.7-3"></a>

###### Treatment delay and accumulation of irreversible disability

> “Prolongation of time until start of therapy was associated with an increased burden of long-term disability.”

Source: [Al-Zuhairy et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31793666/)

> “Treatment initiation within 1 year of onset was significantly associated with lesser post‐treatment disability and greater amplitude of treatment response, in each cohort separately, and in the combined cohort.”
> “Early treatment initiation is a key modifiable determinant of favorable long‐term disability in CIDP. These findings underscore the importance of timely diagnosis and prompt treatment to prevent irreversible axonal damage.”

Source: [Min et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11628630/)

> “Patients who started their initial treatment later experienced a worsening disease course, as reflected by a significant deterioration in their Inflammatory Neuropathy Cause and Treatment (INCAT) leg disability score.”

Source: [Quint et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11377626/)

<a id="topic-2.2.1.7-4"></a>

###### Refractory disease despite standard-of-care therapy

> “Overall, 110 (56%) patients responded to their first therapy and were thus assigned to the status SOC-responder”
> “76 (39%) patients did not respond to their first therapy and were assigned to the status SOC-refractory”
> “SOC-refractory patients had worse clinical outcomes than SOC-responders. Associated factors for SOC-refractory status included the presence of fatigue as a symptom and alcohol dependence.”

Source: [Quint et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11377626/)

<a id="topic-2.2.1.7-5"></a>

###### Cancer risk compared with the general population

> “The observed number of cancer diagnoses corresponded to an incidence rate of 5.63%, with a standardized incidence ratio (SIR) of 2.83 (95% confidence interval [CI]: 1.89–4.39) compared to the expected cancer incidence rate of 2.00%.”

Source: [Choi et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11390450/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Chronic inflammatory demyelinating polyneuropathy

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Pain, fatigue, depression, and EQ-5D and SF-36 scores: systematic review of 7 humanistic burden studies

> “Humanistic burden studies reported on the patient impact of CIDP on health-related quality of life (HRQoL), functioning, psychosocial welfare, productivity, pain, and fatigue”
> “2009 assessed pain and fatigue, using the Numeric Pain Rating Scale (NPRS) and Fatigue Severity Scale (FSS) scores (n = 76), reporting that 17 and 74% of patients with CIDP reported severe pain and severe fatigue, respectively”
> “Two publications reported that 9 and 12.1% of patients had depression, based on hospital anxiety and depression scale (HADS) and the Beck Depression Inventory version II (BDI-II) scores in The Netherlands and Germany, respectively”
> “EuroQol-5D (EQ-5D) scores among patients with CIDP were 0.62 and 0.68 for the UK and Germany, respectively”
> “A study of Dutch patients with CIDP (n = 76) also identified that patients scored below normative 36-Item Short Form Survey Instrument (SF-36) scores (50) for all the domains of the physical component and two of the domains of the mental component (vitality and social functioning)”

Source: [Querol et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8463372/)

<a id="topic-2.2.1.8.1-2"></a>

###### EQ-5D-5L utility, fatigue, and disability in 1056 patients from eight countries, including the United States

> “Data were drawn from the Adelphi CIDP Disease Specific Programme, a cross‐sectional survey with retrospective data collection, conducted in China, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States between September 2022 and April 2023.”
> “Overall, 164 physicians provided data for 1056 patients, with 428 (40.5%) providing self‐reported data.”
> “Overall, mean (SD) patient‐reported scores were 62.1 (20.4) for I‐RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ‐5D‐5L.”
> “Based on mean EQ‐5D‐3L norms in the UK (0.856) and mean EQ‐5D‐5L norms in Germany (0.88), patients experience lower HRQoL in comparison to the general population”
> “Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.8.1-3"></a>

###### EQ-5D-3L utility and work productivity in 146 patients stable on immunoglobulin in the United States, the United Kingdom, and Germany

> “Overall, 146 patients, 52 caregivers, and 81 physicians completed the survey; mean (standard deviation) patient age was 58.1 (12.8) years; time since CIDP diagnosis was 8.8 (9.3) years; 98.6% had received IVIG, and 30.8% had received SCIG.”
> “Mean (SD) EQ-5D-3L utility index and EQ-5D VAS scores in the patient cohort were 0.68 (0.23) and 62.3 (19.4), respectively.”
> “Patients reported that CIDP prevented them (quite a bit or very much) from performing activities (50.7%), affected their social activities with family and friends (39.7%), and imposed financial burden (37.7%).”
> “Among patients who were currently employed, mean (SD) WPAI total productivity impairment pertaining to CIDP was 37.9% (26.6)”

Source: [Yang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396306/)

<a id="topic-2.2.1.8.1-4"></a>

###### Health-state utility values by adjusted INCAT impairment level from EQ-5D data collected in ADHERE

> “In the company’s model, the health state utility values were informed by EQ-5D-5L data collected in ADHERE.”
> “The company estimated the following utility values for each health state:”
> “0.851 for very limited impairment”
> “0.630 for mild impairment”
> “0.426 for moderate impairment”
> “0.084 for severe impairment”
> “-0.216 for very severe impairment.”
> “The EAG explained that the utility values for very severe health states lacked face validity and were too low.”

Source: [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2)

<a id="topic-2.2.1.8.1-5"></a>

###### SF-36 improvement with immune globulin IV 10% versus placebo in 117 trial participants

> “One hundred seventeen patients in a randomized, double-blind, response-conditional crossover trial received immune globulin IV, 10% caprylate/chromatography purified (IGIV-C [Gamunex(R)]), or placebo every 3 weeks for up to 24 weeks in the first period (FP).”
> “In the FP, greater improvements in both SF-36 physical and mental component scores were observed with IGIV-C vs placebo, with a significant improvement in the physical component score (difference 4.4 points; 95% confidence interval [CI] 0.7-8.0).”
> “In the EP, mean SF-36 improvements were generally improved or maintained in participants who continued IGIV-C therapy; however, worsening was observed in participants re-randomized to placebo.”

Source: [Merkies et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19365055/)

<a id="topic-2.2.1.8.1-6"></a>

###### Health-related quality of life measures in chronic inflammatory neuropathies: systematic review

> “There is some evidence suggesting that baseline pre-treatment HRQoL reports are lower in patients with chronic inflammatory neuropathy than in age and gender-matched controls.”
> “Following treatment interventions, improvements in self-reported measures were consistently documented in the physical domain of HRQoL, which in turn correlated with improvements in traditional strength and functional scales.”
> “The impact of available treatments on the quality of life of patients with inflammatory neuropathies remains largely under-investigated.”

Source: [Rajabally and Cavanna (2015)](https://pubmed.ncbi.nlm.nih.gov/25467139/)

<a id="topic-2.2.1.8.1-7"></a>

###### Changes in work and home life in a global survey of 595 respondents with self-reported CIDP

> “Data from an online survey of 595 individuals with self-reported CIDP, recruited by the Guillain–Barré syndrome (GBS)/CIDP Foundation, were used to assess disease and treatment burden.”
> “In "likely" CIDP patients 44% stopped working because of their symptoms and 24% moved to a new home.”
> “IVIg was associated with venous access issues and work/school absenteeism.”
> “CIDP diagnostic confirmation was not performed in any of the survey respondents.”

Source: [Allen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854453/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Two-year all-cause costs and resource use versus matched controls in 790 newly diagnosed US adults

> “This retrospective case-control analysis was conducted using data from the IQVIA Real-World Data Adjudicated Claims.”
> “The final sample comprised a total of 790 cases matched to 790 controls.”
> “Cases had 7.5x higher mean total costs ($116,330 vs. $15,586, p<0.0001).”
> “Important cost drivers were costs for outpatient ancillary, radiology and HCPCS drugs (mean $76,366 vs. $4,292) and costs for inpatient care (mean $16,357 vs. $2,862) (both p<0.0001).”
> “Among cases, CIDP therapy (inclusive of both outpatient pharmacy and medical claims) accounted for 51.2% of mean total costs.”
> “From treatment initiation to the end of the 24-month follow-up, corticosteroid patients had mean (SD) CIDP therapy costs of about $7,900 ($35,000) while IVIg patients had mean CIDP therapy costs of $165,000 ($170,000).”

Source: [Divino et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6198979/)

<a id="topic-2.2.1.8.2-2"></a>

###### First-year all-cause costs by immunoglobulin use pattern in 3409 US adults

> “A retrospective cohort study was conducted using a US claims dataset (Komodo Health closed claims, Jan 2016 – Dec 2020).”
> “62% (n=1113/1803) were chronic IG users, and 38% (n=690/1803) were intermittent IG users.”
> “Based on US claims data, the economic burden for adult patients with CIDP was driven by treatment pattern, with substantial burden observed in patients receiving chronic IG.”

Source: [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957)

| Measure, year 1 after index | Value |
| --- | --- |
| All-cause outpatient visits, all patients | “31.74” |
| All-cause inpatient days, patients with at least 1 visit | “2.40” |
| Mean all-cause total cost, all patients | “$105,554” |
| Mean annual all-cause total cost, chronic immunoglobulin users | “$247,456” |

Source: [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957)

<a id="topic-2.2.1.8.2-3"></a>

###### Two-year CIDP-specific costs by treatment cohort in US commercial claims

> “This retrospective cohort study evaluated the treatment patterns and CIDP-related healthcare costs over a 2-year follow-up period for patients with newly diagnosed CIDP who had commercial insurance, using claims data from the IMS LifeLink PharMetrics Plus Claims database between 2009 through 2014.”
> “The mean total CIDP-specific 2-year follow-up costs were highest for the cohort that received IVIG alone ($119,928) or with an additional therapy ($133,334) and lowest for patients who received active surveillance ($3723) or steroids alone ($3101).”
> “When costs by site of care were investigated, the majority of IVIG infusion costs were found to be in the home rather than in the clinic or hospital setting.”

Source: [Guptill et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6611518/)

<a id="topic-2.2.1.8.2-4"></a>

###### Cost of illness and cost drivers in the United Kingdom, France, Germany, and the United States: systematic review

> “CIDP cost of illness varied across geographies, from £22,086 (2007 costs) annually per patient in the UK, through €47,823 (2017 costs) and €45,000 (2013 costs) annually per patient in France and Germany, respectively, to $116,330 (costs converted to USD 2016 values) over 2 years in the USA”
> “Similarly, in the US, drug-related costs represented 57% of total costs, followed by inpatient and outpatient hospital services (35%)”
> “In the US, the majority of IVIG infusions occurred at home (72%), followed by physician offices (16%) and outpatient hospitals (11%)”
> “In the UK, loss of productivity was estimated to cost £5815 per patient per year, and projected to cost the UK economy a total of £9.7 M per year, accounting for 26% of the total cost of illness”

Source: [Querol et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8463372/)

<a id="topic-2.2.1.8.2-5"></a>

###### Quarterly societal costs and the share attributable to immunoglobulin in 108 patients in Germany

> “In total, 108 patients were recruited from 3 specialized neuroimmunological clinics.”
> “Total quarterly costs were €11,333. Direct costs contributed to 83% of total costs (€9,423), whereas indirect costs accounted for 17% (€1,910) of total costs. The cost of intravenous immunoglobulin (IVIg) was the main determinant of total costs (67%).”
> “Reduced health-related quality of life and depressive symptoms were identified as independent predictors of higher total costs.”

Source: [Mengel et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30073683/)

<a id="topic-2.2.1.8.2-6"></a>

###### Hospitalizations, mobility aids, and productivity losses by disability level in 542 patients in five European countries

> “Neurologists provided data on treatment, informal care, hospitalizations, mobility aids, and home modifications for 542 patients, while lost productivity was reported by a subset of patients ( n = 199).”
> “Hospitalizations in the 12 months prior to the survey were more frequent with greater disability (mild 7.0%, moderate 14.5%, severe 21.6%; p < 0.001), as were emergency admissions (1.0, 9.9, 13.7% respectively; p < 0.001) and ICU stays (0.0, 0.7, 3.9% respectively; p = 0.001).”
> “The use of mobility aids (19.1, 56.1, 89.7% respectively) and home modifications (12.8, 45.8, 74.2% respectively) also rose significantly with severity ( p < 0.001 for both).”
> “Finally, work productivity losses among employed patients and activity impairment rose as disability increased (average percentage of productivity loss: mild 21.8%, moderate 44.0%, severe: 67.3%, p < 0.001; average daily activity impairment: mild 28.6%, moderate: 44.6%, severe: 68.1%, p < 0.001).”
> “As shown in Figure 4A , the proportion of patients employed at the time of the survey decreased with increasing disability severity (mild: 71.4%; moderate: 69.8%; severe: 39.1%; p = 0.049).”

Source: [Brackx et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13368673/)

<a id="topic-2.2.1.8.2-7"></a>

###### Annual immunoglobulin costs per person and savings from cessation trials in a UK center

> “IVIg is a relatively scarce and expensive resource at a cost of £71/g, with immunomodulatory use representing £300 million per year of National Health Service (NHS) UK spending, and similar expenditure in other high income countries”
> “The median cost of IVIg was £97 705 per person/year, at a median frequency of 2.4 days/month in the day care unit (£9213 per person/year), giving a total median cost of £106 918 per person/year.”
> “The cost saving associated with successful IVIg cessation in eight individuals was £855 344 per year, including IVIg spend and daycare unit costs.”

Source: [Koay et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11836592/)

<a id="topic-2.2.1.8.2-8"></a>

###### Annual cost of immunoglobulin maintenance treatment by route of administration in Spain

> “A cost-analysis model based on a decision tree was developed to evaluate the annual cost per patient treated with each immunoglobulin from a societal perspective.”
> “The annual cost for a patient with CIDP receiving maintenance treatment was €109,212.67 with IVIG, €98,161.97 with c-SCIG, and €98,191.37 with f-SCIG.”
> “The main driver of the difference between SCIG and IVIG cost was treatment administration (−€10,705.78).”

Source: [de Pedro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13000016/)

<a id="topic-2.2.1.8.2-9"></a>

###### Annual health plan paid cost per patient and share attributable to immunoglobulin in US commercial health plans, 2011

> “The most prescribed therapies were intravenous immunoglobulin (IVIg) (26% of patients), gabapentin (26%), and prednisone (16%).”
> “The annual health plan paid cost was $56,953. Pharmacy cost was the major cost driver (57% of the total), and IVIg totaled 90% of the pharmacy costs.”

Source: [Guptill et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24639235/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Chronic inflammatory demyelinating polyneuropathy on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Informal caregiving hours and effect on caregiver employment in 542 patients in five European countries

> “In the overall sample, 26.7% of patients required a caregiver, with a mean of 9.1 h of care per week (SD: 24.1).”
> “The partner or spouse was the primary caregiver in 84.3% of cases, and caregiving affected the caregiver’s work and daily activities in 41.4 and 78.9% of cases, respectively.”
> “As shown in Figure 1A , the proportion of patients requiring informal (unpaid) care increased significantly with disability (mild: 7.2%; moderate: 31.2%; severe: 62.9%; p < 0.001).”
> “A work-related impact was reported in 20.0, 35.3, and 52.0% of caregivers for patients with mild, moderate, and severe disability, respectively.”
> “The most reported work-related impacts were reduced working hours (mild: 0.0%; moderate: 26.5%; severe: 20.0%) and cessation of work (mild: 13.3%; moderate: 0.0%; severe: 16%).”

Source: [Brackx et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13368673/)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver use and hours of care in a US real-world survey

> “The Adelphi CIDP Disease Specific Programme™ is a real-world, cross-sectional survey of US CIDP patients and their neurologists conducted between September 2022 and April 2023.”
> “Nearly a third required caregiver help, usually from a partner/spouse (80%). On average, patients needed 5 hours of care/help per day (n=18).”

Source: [Nowacek et al. (2025)](https://www.mdaconference.org/abstract-library/employment-daily-activities-and-caregiver-burden-in-cidp-results-of-a-real-world-us-survey/)

<a id="topic-2.2.1.8.3-3"></a>

###### Caregiver health-related quality of life, productivity, and financial burden in 52 caregivers

> “Most patients and caregivers were from the USA (87.0% and 65.4%, respectively; Table 1 ), whereas the distribution of physicians was more even across the USA, the UK, and Germany”
> “Among caregivers, mean (SD) EQ-5D-3L utility index and EQ-5D VAS scores were 0.79 (0.28) and 76.8 (15.6), respectively.”
> “More than a quarter (28.8%) of the caregivers reported that CIDP affected (quite a bit or very much) their social activities with family and/or friends, while 36.5% reported that CIDP imposed financial burden on themselves and their family.”
> “Among caregivers who were employed, mean (SD) WPAI total productivity impairment pertaining to CIDP was 30.8% (21.0)”

Source: [Yang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396306/)

<a id="topic-2.2.1.8.3-4"></a>

###### Carer utility decrement applied in the NICE appraisal of efgartigimod

> “The EAG thought that the company’s EQ-5D-5L data from 21 UK-based carers of people with CIDP in a cross-sectional observational survey of burden on informal carers was more robust. This reported a carer utility of 0.798.”
> “The difference of - 0.0121 between these utility values was used as the carer utility decrement for all carers.”

Source: [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2)

<a id="topic-2.2.1.8.3-5"></a>

###### Caregiver disutility removed from the CDA-AMC reanalysis of efgartigimod

> “No evidence was available on caregiver disutility in the indicated population, and the proxy values used were uncertain given the uncertainty in how health states were defined.”
> “CDA-AMC removed caregiver disutility from the reanalysis.”

Source: [CDA-AMC efgartigimod alfa reimbursement review (2026)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0894r/3193?inline=1)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Misdiagnosis in 59 consecutive patients referred to a US center with a diagnosis of CIDP

> “A retrospective study of 59 consecutive patients referred with a diagnosis of CIDP was performed.”
> “Forty-seven percent of patients referred with a diagnosis of CIDP failed to meet minimal CIDP diagnostic requirements.”
> “Patients frequently reported improvements after being treated with immunotherapy, even if the CIDP diagnosis was incorrect.”
> “Over-reliance on subjective patient-reported perception of treatment benefit, liberal electrophysiologic interpretation of demyelination, and placing an overstated importance on mild or moderate cytoalbuminologic dissociation are common diagnostic errors.”

Source: [Allen and Lewis (2015)](https://pubmed.ncbi.nlm.nih.gov/26180143/)

<a id="topic-2.2.1.8.4-2"></a>

###### Electrodiagnostic interpretation errors in 86 referred patients

> “Thirty-nine of 86 patients were found not to have CIDP. Initial electrodiagnostic data quality was generally acceptable, but initial electrodiagnostic conclusions were confirmed in only 45% of misdiagnosed studies.”

Source: [Allen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29053880/)

<a id="topic-2.2.1.8.4-3"></a>

###### Overdiagnosis and immunoglobulin exposure before referral at a Dutch tertiary center

> “A referral diagnosis of CIDP was revised in 32% of patients (31/96; overdiagnosis).”
> “In the overdiagnosed patients, 20% of muscle weakness was asymmetric, 48% lacked proximal muscle weakness, 29% only had distal muscle weakness, 65% did not fulfil the electrodiagnostic criteria for CIDP, 74% had an elevated cerebrospinal fluid (CSF) protein level, and 97% had another type of neuropathy.”
> “Treatment Before referral, 52% of overdiagnosed patients ( n = 16) were treated for CIDP with intravenous immunoglobulins (IVIg; n = 12), corticosteroids ( n = 1), or IVIg and corticosteroids ( n = 3).”

Source: [Broers et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8252611/)

<a id="topic-2.2.1.8.4-4"></a>

###### Initial misdiagnosis and diagnostic delay in 1056 patients from eight countries

> “Overall, initial misdiagnosis occurred in 37.2% of patients, with a median (interquartile range) diagnostic delay of 6.0 (3.0–12.0) months.”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.8.4-5"></a>

###### Electrodiagnostic testing before immunoglobulin initiation in 3975 US claims patients

> “Of 32,090 patients with CIDP identified, 3975 (mean age 57 years) subsequently initiated IVIG.”
> “CIDP-related laboratory/diagnostic procedures were performed in approximately 20– > 40% of patients in the 3 months prior to IVIG initiation (63.7% underwent electrodiagnostic/nerve conduction testing in the 6 months prior to IVIG initiation).”
> “In addition, some patients received IVIG therapy in the absence of electrodiagnostic or nerve conduction tests.”

Source: [Layton et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10310640/)

<a id="topic-2.2.1.8.4-6"></a>

###### Electrophysiological findings as a US payer requirement for immunoglobulin coverage

> “Several US payers mandate positive electrophysiological findings on at least three of four tests (per guidelines from the American Academy of Neurology [AAN]) as part of medical necessity for CIDP treatment, particularly intravenous immunoglobulin (IVIg)”

Source: [Divino et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6198979/)

<a id="topic-2.2.1.8.4-7"></a>

###### Treatment cost in Charcot-Marie-Tooth disease misdiagnosed as CIDP compared with the cost of genetic testing

> “Among 1104 CIDP cases, we identified 35 CMT patients misdiagnosed as CIDP (3.2%).”
> “Treatment cost in these 35 misdiagnosed patients was estimated at 4.6 million euros (M€), whereas the cost of CMT genetic analysis in 1104 patients was estimated at 2.7 M€.”
> “Importantly, the cost of treating these 35 misdiagnosed patients was significantly higher than the cost of performing CMT genetic analysis in 1104 patients (4.6 M€ vs. 2.7 M€), suggesting that CMT genetic investigations should be more widely used before diagnosing CIDP.”

Source: [Hauw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34060689/)

<a id="topic-2.2.1.8.4-8"></a>

###### Costs of POEMS syndrome misdiagnosed as CIDP and cost-effectiveness of VEGF testing

> “Delay in diagnosis is common with 55% of patients initially incorrectly diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).”
> “Treatment associated with an incorrect CIDP diagnosis led to total wasted healthcare expenditures of between £808 550 and £1 111 756 across our cohort, with an average cost-per-POEMS-patient misdiagnosed of £14 701 to £20 214.”
> “Introducing mandatory VEGF testing for patients with acquired demyelinating neuropathy would lead to annual cost-savings of £107 398 for the National Health Service and could prevent misdiagnosis in 16 cases per annum.”

Source: [Marsh et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33106368/)

<a id="topic-2.2.1.8.4-9"></a>

###### Electrodiagnostic confirmation as a condition of reimbursement for efgartigimod in Canada

> “Vyvgart SC should only be covered for adults with CIDP confirmed by electrodiagnostic testing, or for adults with possible CIDP based on clinical features and at least 2 supportive criteria consistent with current guidelines.”

Source: [CDA-AMC efgartigimod alfa reimbursement recommendation (2026)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/SR0894/2990?inline=1)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Corticosteroids

<a id="topic-2.2.2.1.1-1"></a>

###### Guideline recommendation for initial treatment

> “(a) intravenous immunoglobulin (IVIg) or corticosteroids are strongly recommended as initial treatment in typical CIDP and CIDP variants”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="topic-2.2.2.1.1-2"></a>

###### Certainty of randomized evidence for corticosteroids

> “One non‐blinded RCT comparing prednisone with no treatment in 35 eligible participants did not measure the primary outcome for this systematic review.”
> “Neuropathy Impairment Scale scores after 12 weeks improved in 12 of 19 participants randomised to prednisone, compared with five of 16 participants randomised to no treatment (risk ratio (RR) for improvement 2.02 (95% confidence interval (CI) 0.90 to 4.52; very low‐quality evidence).”
> “There was little or no difference in number of participants who achieved remission (RR 1.11; 95% CI 0.50 to 2.45 in favour of monthly dexamethasone; moderate‐quality evidence), or change in disability or impairment after one year (low‐quality evidence).”
> “Nevertheless, corticosteroids are commonly used in practice, supported by very low‐quality evidence from observational studies.”

Source: [Hughes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6747552/)

<a id="topic-2.2.2.1.1-3"></a>

###### Pulsed dexamethasone versus daily prednisolone: remission at 12 months

> “The primary outcome measure was remission at 12 months, defined as improvement of at least three points on the Rivermead mobility index and improvement of at least one point on the inflammatory neuropathy cause and treatment disability scale.”
> “Between December, 2003, and December, 2008, 40 patients were treated: 24 received dexamethasone and 16 received prednisolone. At 12 months, 16 patients were in remission: ten in the dexamethasone group and six in the prednisolone group (odds ratio [OR] 1.2, 95% CI 0.3-4.4).”
> “Most adverse events were minor and did not differ substantially between treatment groups; however, sleeplessness and Cushing's face occurred more often in the prednisolone group.”

Source: [van Schaik et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20133204/)

<a id="topic-2.2.2.1.1-4"></a>

###### Long-term remission after corticosteroid courses

> “Cure (>5 years off treatment) or remission according to the CDAS criteria after 1 or 2 courses of pulsed dexamethasone or daily prednisolone was achieved in 10 out of 39 patients (26%).”
> “Half of the patients who were in remission after initial treatment experienced a relapse (median treatment-free interval: 17.5 months for dexamethasone, 11 months for prednisolone).”

Source: [Eftimov et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22442436/)

<a id="topic-2.2.2.1.1-5"></a>

###### Intravenous methylprednisolone versus intravenous immunoglobulin over 6 months

> “More patients stopped methylprednisolone (11 [52%] of 21) than IVIg (three [13%] of 24; relative risk 0·54, 95% CI 0·34-0·87; p=0·0085).”
> “Reasons for discontinuation were lack of efficacy (eight in the methylprednisolone group vs three in the IVIg group), adverse events (one in the methylprednisolone group), or voluntary withdrawal (two in the methylprednisolone group).”
> “After therapy discontinuation, more patients on IVIg worsened and required further therapy (eight [38%] of 21) than did those on methylprednisolone (none of ten; p=0·0317).”

Source: [Nobile-Orazio et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22578914/)

<a id="topic-2.2.2.1.1-6"></a>

###### Oral prednisolone versus intravenous immunoglobulin: randomized crossover trial

> “This multicenter, randomized, double-blind, crossover trial compared a six week course of oral prednisolone tapering from 60 mg to 10 mg daily with intravenous immunoglobulin (IVIg) 2.0 g/kg given over one to two days for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).”
> “Twenty-four of the thirty-two randomized patients completed both treatment periods.”
> “There was slightly, but not significantly, more improvement after IVIg than with prednisolone, the mean difference between the groups in change in disability grade being 0.16 (95% CI = -0.35 to 0.66).”
> “A serious adverse event (psychosis) attributable to treatment occurred in one patient while on prednisolone and in none with IVIg.”

Source: [Hughes et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11506402/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Intravenous Immunoglobulin

<a id="topic-2.2.2.1.2-1"></a>

###### Guideline recommendation in motor CIDP

> “(c) IVIg should be considered as first-line treatment in motor CIDP (Good Practice Point)”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="topic-2.2.2.1.2-2"></a>

###### Immune globulin intravenous versus placebo: adjusted INCAT response through week 24

> “117 patients with CIDP who met specific neurophysiological inflammatory neuropathy cause and treatment (INCAT) criteria participated in a randomised, double-blind, placebo-controlled, response-conditional crossover trial.”
> “During the first period, 32 of 59 (54%) patients treated with IGIV-C and 12 of 58 (21%) patients who received placebo had an improvement in adjusted INCAT disability score that was maintained through to week 24 (treatment difference 33.5%, 95% CI 15.4-51.7; p=0.0002).”
> “During the extension phase, participants who continued to receive IGIV-C had a longer time to relapse than did patients treated with placebo (p=0.011).”
> “The incidence of serious adverse events per infusion was 0.8% (9/1096) with IGIV-C versus 1.9% (11/575) with placebo. The most common adverse events with IGIV-C were headache, pyrexia, and hypertension.”

Source: [Hughes et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18178525/)

<a id="topic-2.2.2.1.2-3"></a>

###### Pooled randomized evidence for intravenous immunoglobulin

> “We included nine RCTs with 372 participants (235 male) from Europe, North America, South America, and Israel.”
> “IVIg compared with placebo increases the probability of significant improvement in disability within six weeks of the start of treatment (risk ratio (RR) 2.40, 95% confidence interval (CI) 1.72 to 3.36; number needed to treat for an additional beneficial outcome (NNTB) 4, 95% CI 3 to 5; 5 trials, 269 participants; high‐certainty evidence).”
> “During this period, IVIg probably has similar efficacy to oral prednisolone and IVMP.”
> “Further research is needed to assess the long‐term benefits and harms of IVIg relative to other treatments.”

Source: [Bus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10865446/)

<a id="topic-2.2.2.1.2-4"></a>

###### Single-arm induction and maintenance study: responder rate

> “Patients received one induction dose of Privigen (2 g/kg body weight [bw]) and up to seven maintenance doses (1 g/kg bw) at 3-week intervals.”
> “The overall responder rate at completion was 60.7% (95% confidence interval [CI]: 42.41%–76.43%).”
> “Two serious AEs of hemolysis were reported that resolved after discontinuation of treatment.”

Source: [Léger et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3910165/)

<a id="topic-2.2.2.1.2-5"></a>

###### Maintenance dose-ranging study: response by dose

> “Patients were randomized 1:2:1 to receive the standard intravenous immunoglobulin induction dose and then either 0.5, 1.0 or 2.0 g/kg maintenance doses every 3 weeks.”
> “The response rate was 80% (55/69 patients) [95% confidence interval (CI): 69–88%] in the 1.0 g/kg group, 65% (22/34; CI: 48–79%) in the 0.5 g/kg group, and 92% (33/36; CI: 78–97%) in the 2.0 g/kg group.”
> “While the proportion of responders was higher with higher maintenance doses, logistic regression analysis showed that the effect on response rate was driven by a significant difference between the 0.5 and 2.0 g/kg groups, whereas the response rates in the 0.5 and 2.0 g/kg groups did not differ significantly from the 1.0 g/kg group.”

Source: [Cornblath et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9050528/)

<a id="topic-2.2.2.1.2-6"></a>

###### Rescue treatment of relapse after subcutaneous immunoglobulin or placebo

> “Overall, 20 patients received IVIG 10% ( n = 4 [fSCIG 10%‐relapse group]; n = 16 [placebo‐relapse group]).”
> “Responder rate (95% confidence interval) was 100.0% (80.6%–100.0%) in the placebo‐relapse group and 95.0% (76.4%–99.1%) in the overall‐relapse population.”
> “Across all patients, median time to functional improvement was 25 days.”

Source: [Pasnoor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006664/)

<a id="topic-2.2.2.1.2-7"></a>

###### FDA-approved intravenous immunoglobulin products for CIDP: indications and dosing

> “GAMUNEX-C FlexBag is indicated for the treatment of CIDP in adults to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.”
> “GAMUNEX-C FlexBag may be initially administered as a total loading dose of 2 g/kg (20 mL/kg) given in divided doses over two to four consecutive days.”
> “GAMUNEX-C FlexBag may be administered as a maintenance infusion of 1 g/kg (10 mL/kg) administered over 1 day or divided into two doses of 0.5 g/kg (5 mL/kg) given on two consecutive days, every 3 weeks.”

Source: [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download)

> “Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults (1.3)”
> “Limitations of Use: PRIVIGEN maintenance therapy in CIDP has not been studied beyond 6 months. (1.3)”
> “Loading dose: 2 g/kg (20 mL/kg) in divided doses over 2 to 5 consecutive days Maintenance dose: 1 g/kg (10 mL/kg) administered in 1 to 2 infusions on consecutive days, every 3 weeks”

Source: [Privigen prescribing information (2025)](https://www.fda.gov/media/83304/download)

> “PANZYGA is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.”
> “Loading dose: 2 g/kg (20 mL/kg), divided into 2 daily doses of 1 g/kg (10 mL/kg) given on 2 consecutive days Maintenance dose: 1-2 g/kg (10-20 mL/kg) every 3 weeks divided in 2 doses given over 2 consecutive days”

Source: [Panzyga prescribing information (2021)](https://www.fda.gov/media/115397/download)

> “Therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). (1.3)”
> “Safety and effectiveness of GAMMAGARD LIQUID has not been studied in immunoglobulin-naïve patients with CIDP. (1.3)”
> “Induction dose is 2 g/kg in divided doses over 2 to 5 consecutive days, followed by maintenance infusions. Maintenance dose is 1 g/kg in divided doses over 1 to 4 consecutive days, every 3 weeks.”

Source: [Gammagard Liquid prescribing information (2024)](https://www.fda.gov/media/191699/download)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Subcutaneous Immunoglobulin

<a id="topic-2.2.2.1.3-1"></a>

###### Guideline recommendation for maintenance treatment

> “(d) for maintenance treatment, IVIg, subcutaneous immunoglobulin or corticosteroids are recommended”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="topic-2.2.2.1.3-2"></a>

###### Weekly subcutaneous immunoglobulin versus placebo: relapse or withdrawal over 24 weeks

> “We randomly allocated participants to 0·2 g/kg or 0·4 g/kg of a 20% SCIg solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24 weeks.”
> “In the intention-to-treat set, 36 (63% [95% CI 50-74]) patients on placebo, 22 (39% [27-52]) on low-dose SCIg, and 19 (33% [22-46]) on high-dose SCIg had a relapse or were withdrawn from the study for other reasons (p=0·0007).”
> “Absolute risk reductions were 25% (95% CI 6-41) for low-dose versus placebo (p=0·007), 30% (12-46) for high-dose versus placebo (p=0·001), and 6% (-11 to 23) for high-dose versus low-dose (p=0·32).”
> “Causally related adverse events occurred in 47 (27%) patients (ten [18%] in the placebo group, 17 [30%] in the low-dose group, and 20 [34%] in the high-dose group).”

Source: [van Schaik et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29122523/)

<a id="topic-2.2.2.1.3-3"></a>

###### Facilitated subcutaneous immunoglobulin versus placebo: relapse over 6 months

> “fSCIG 10% was administered at the same dose (or matching placebo volume) and interval as pre-randomization IVIG.”
> “CIDP relapse was reduced with fSCIG 10% versus placebo (n = 6 [9.7%; 95% confidence interval 4.5%, 19.6%] vs n = 22 [31.4%; 21.8%, 43.0%], respectively; absolute difference: -21.8% [-34.5%, -7.9%], p = .0045).”
> “Adverse events (AEs) were more frequent with fSCIG 10% (79.0% of patients) than placebo (57.1%), but severe (1.6% vs 8.6%) and serious AEs (3.2% vs 7.1%) were less common.”

Source: [Bril et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37314318/)

<a id="topic-2.2.2.1.3-4"></a>

###### Long-term facilitated subcutaneous immunoglobulin extension: relapse and tolerability

> “The study provided 220 patient‐years of follow‐up data from 85 patients. Median (range) exposure was 33 (0–77) months. Patients received fSCIG every 4 weeks (88.2%) or every 3 weeks (11.8%).”
> “Relapse occurred in 10 of 77 patients (13.0%); annual relapse rate was 4.5%.”
> “fSCIG‐related AEs ( n = 798) included infusion site reactions such as pain, redness, and pruritus.”

Source: [Hadden et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625974/)

<a id="topic-2.2.2.1.3-5"></a>

###### Pooled randomized evidence for subcutaneous immunoglobulin

> “Four RCTs with 360 randomised participants met our eligibility criteria.”
> “SCIg maintenance treatment probably reduces the risk of clinically significant deterioration in disability within 12 to 24 weeks compared to placebo (RR 0.40, 95% CI 0.28 to 0.56; 3 studies, 333 participants; moderate‐certainty evidence).”
> “We could not evaluate the difference between SCIg and IVIg as induction treatment in terms of rate of improvement in disability, change in grip strength, or frequency of local or systemic adverse effects, as these data were not available.”

Source: [Bus et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13459082/)

<a id="topic-2.2.2.1.3-6"></a>

###### FDA-approved subcutaneous immunoglobulin products for CIDP: indications and dosing

> “HIZENTRA is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.”
> “Initiate therapy with HIZENTRA 1 week after the last IGIV infusion.”
> “Recommended subcutaneous dose is 0.2 g/kg (1 mL/kg) body weight per week.”

Source: [Hizentra prescribing information (2021)](https://www.fda.gov/media/78466/download)

> “HYQVIA is indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults.”
> “The starting dose and dosing frequency of HYQVIA is the same as the patient’s previous IGIV treatment. The typical dosing interval range in the clinical trial for HYQVIA was 2 to 4 weeks.”

Source: [HyQvia prescribing information (2026)](https://www.fda.gov/media/89844/download)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Plasma Exchange

<a id="topic-2.2.2.1.4-1"></a>

###### Guideline recommendation after failure of immunoglobulin and corticosteroids

> “(b) plasma exchange is strongly recommended if IVIg and corticosteroids are ineffective”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="topic-2.2.2.1.4-2"></a>

###### Pooled randomized evidence for plasma exchange

> “Primary outcome measure: one cross‐over trial including 18 participants showed after four weeks, 2 (95% confidence interval (CI) 0.9 to 3.1) points more improvement on an 11‐point disability scale with plasma exchange (10 exchanges over four weeks) than with sham exchange.”
> “Non‐randomised evidence indicates that plasma exchange induces adverse events in 3% to 17% of procedures.”
> “Adverse events related to difficulty with venous access, use of citrate, and haemodynamic changes are not uncommon.”

Source: [Mehndiratta et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6734114/)

<a id="topic-2.2.2.1.4-3"></a>

###### Plasma exchange versus sham exchange: parallel-group trial

> “We performed a prospective double-blind trial in which patients with static or worsening disease were randomly assigned to plasma exchange (n = 15) or to sham exchange (n = 14) for three weeks.”
> “We conclude that for some patients with chronic inflammatory demyelinating polyradiculoneuropathy, plasma exchange has an ameliorating effect on neurologic dysfunction and nerve conduction, but in others no improvement is observed.”

Source: [Dyck et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3511382/)

<a id="topic-2.2.2.1.4-4"></a>

###### Plasma exchange versus sham exchange: double-blind crossover trial

> “A primary 'intention to treat' analysis showed significant improvement with PE in all clinical outcome measures: NDS by 38 points, P < 0.001; CG by 1.6 points, P < 0.001; GS by +13 kg, P < 0.003”
> “We conclude that PE is a very effective adjuvant therapy for CIDP of both chronic progressive and relapsing course; concurrent immunosuppressive drug treatment is required.”
> “Exchange treatments should be given two to three times per week until improvement is established; the treatment frequency should then be tapered over several months.”

Source: [Hahn et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8813270/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Immunosuppressants and Rituximab

<a id="topic-2.2.2.1.5-1"></a>

###### Guideline recommendation when maintenance doses are high

> “(e) if the maintenance dose of any of these is high, consider either combination treatments or adding an immunosuppressant or immunomodulatory drug (Good Practice Point)”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="topic-2.2.2.1.5-2"></a>

###### Pooled randomized evidence for immunosuppressants and immunomodulators

> “Four trials fulfilled the selection criteria: one of azathioprine (27 participants), two of IFN beta‐1a (77 participants in total) and one of methotrexate (60 participants).”
> “None of the trials showed significant benefit in any of the outcomes selected by their authors.”
> “None of the trials was large enough to rule out small or moderate benefit.”

Source: [Mahdi-Rogers et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6481566/)

<a id="topic-2.2.2.1.5-3"></a>

###### Methotrexate versus placebo: corticosteroid or immunoglobulin dose reduction

> “14 (52%) of 27 taking methotrexate and 14 (44%) of 32 taking placebo had a greater than 20% reduction in mean weekly dose of corticosteroids or intravenous immunoglobulin (adjusted odds ratio 1.21, 95% CI 0.40-3.70).”
> “Oral methotrexate 15 mg weekly showed no significant benefit, but limitations in the trial design and the high rate of response in the placebo group meant that a treatment effect could not be excluded.”

Source: [RMC Trial Group (2009)](https://pubmed.ncbi.nlm.nih.gov/19136303/)

<a id="topic-2.2.2.1.5-4"></a>

###### Rituximab versus placebo: worsening after immunoglobulin discontinuation

> “In this randomized, double-blind, placebo-controlled study, conducted at seven Italian hospitals, CIDP patients under immunoglobulin therapy were assigned to receive either rituximab (1 g on Days 1, 15 and 180 ± 7) or placebo.”
> “A similar proportion of patients in both the rituximab (12/19, 63.2%) and placebo (12/18, 66.6%) groups worsened at Month 12 [odds ratio (OR) 0.86; 95% confidence interval (CI) 0.22–3.32].”
> “The median time to worsening was 5 months for rituximab and 2 months for placebo (Log-rank P = 0.4372).”

Source: [Nobile-Orazio et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11967823/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Neonatal Fc Receptor Blockers

<a id="topic-2.2.2.1.6-1"></a>

###### FDA-approved neonatal Fc receptor blocker for CIDP: indication and dosing

> “VYVGART HYTRULO is indicated for the treatment of adult patients with:”
> “The recommended dosage of VYVGART HYTRULO prefilled syringe is 1,000 mg / 10,000 units (1,000 mg efgartigimod alfa and 10,000 units hyaluronidase) administered subcutaneously over approximately 20 to 30 seconds as once weekly injections.”
> “The recommended dosage of VYVGART HYTRULO vial is 1,008 mg / 11,200 units (1,008 mg efgartigimod alfa and 11,200 units hyaluronidase) administered subcutaneously over approximately 30 seconds to 90 seconds as once weekly injections.”

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.2.2.1.6-2"></a>

###### Approval for CIDP

> “In June 2024, Vyvgart Hytrulo, marketed by argenx, was approved for the treatment of CIDP.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.2.2.1.6-3"></a>

###### Subcutaneous efgartigimod randomized withdrawal trial: response and relapse

> “Participants with evidence of clinically meaningful deterioration entered an open-label phase of weekly 1000 mg subcutaneous efgartigimod PH20 for no longer than 12 weeks (stage A).”
> “Between April 15, 2020, and May 11, 2023, 629 participants were screened; 322 (114 female, 208 male) entered stage A, of whom 214 (66%, 95% CI 61·0-71·6) had confirmed ECI.”
> “Subcutaneous efgartigimod PH20 significantly reduced the risk of relapse versus placebo (hazard ratio 0·39 [95% CI 0·25-0·61]; p<0·0001). 31 (27·9% [19·6-36·3]) participants given subcutaneous efgartigimod PH20 had a relapse versus 59 (53·6% [44·3-63·0]) given placebo.”
> “In stage B, TEAEs occurred in 71 (64%) participants on subcutaneous efgartigimod PH20 and 62 (56%) participants on placebo, and serious TEAEs in six (5%) on subcutaneous efgartigimod PH20 and six (5%) on placebo.”

Source: [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/)

<a id="topic-2.2.2.1.6-4"></a>

###### Open-label extension: long-term safety and function

> “At interim data cut‐off (February 16, 2024), 228/229 eligible participants advanced to ADHERE+.”
> “Prolonged efgartigimod exposure did not increase the incidence ( n = 171/228 [75.0%]) or severity of TEAEs (grade ≥ 3 TEAEs, n = 41/228 [18.0%]); regardless of immunoglobulin G level, there was a low incidence of infections.”
> “Stage A responders reported long‐term clinically meaningful improvements in mean aINCAT (decreased by 1.2 points), I‐RODS centile metric (increase of 8.8 points), and GS scores (increase of 17.5 kPa) from run‐in baseline to ADHERE+ week 36, irrespective of stage B treatment.”

Source: [Allen et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375598/)

<a id="topic-2.2.2.1.6-5"></a>

###### Subcutaneous efgartigimod randomized withdrawal trial: registry participant flow

> “population of treatment-naïve participants and participants who were previously treated for CIDP (corticosteroids, IVIg, or SCIg) with confirmed, active disease and a wide range of disease severity.”
> “A total of 322 participants received efgartigimod PH20 SC in Stage A, and 221 participants were randomized in a 1:1 ratio to efgartigimod PH20 SC (N=111) or placebo (N=110) in Stage B.”

Source: [ClinicalTrials.gov NCT04281472](https://clinicaltrials.gov/study/NCT04281472?tab=results)

<a id="topic-2.2.2.1.6-6"></a>

###### Subcutaneous efgartigimod randomized withdrawal trial: registry results for stage B time-to-event and disability outcomes

| Stage B outcome | Efgartigimod PH20 SC | Placebo PH20 SC |
| --- | --- | --- |
| Median time to first adjusted INCAT deterioration, days (95% CI) | “NA[1] (NA to NA)” | “140.0[2] (75.0 to NA)” |
| Median time to CIDP disease progression, days (95% CI) | “NA[1] (247.0 to NA)” | “85 (50.0 to 253.0)” |
| Mean (SD) change in adjusted INCAT score from stage B baseline | “0.1(1.08)” | “0.9(1.98)” |

Source: [ClinicalTrials.gov NCT04281472](https://clinicaltrials.gov/study/NCT04281472?tab=results)

<a id="topic-2.2.2.1.6-7"></a>

###### Subcutaneous efgartigimod randomized withdrawal trial: registry definitions for stage B outcomes

> “Insufficient number of participants with events, less than 50% of the participants had clinically deteriorated.”
> “Time to chronic inflammatory demyelinating polyneuropathy (CIDP) disease progression is defined by the time from first dose of double-blind IMP to the first I-RODS score decrease ≥4 points compared to Stage B baseline using the centile metric.”
> “Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) scores range from 0-10 with a score of 10 indicating the greatest degree of disability.”

Source: [ClinicalTrials.gov NCT04281472](https://clinicaltrials.gov/study/NCT04281472?tab=results)

<a id="topic-2.2.2.1.6-8"></a>

###### Subcutaneous efgartigimod randomized withdrawal trial: registry all-cause mortality and serious adverse events

| Event | Stage A efgartigimod PH20 SC | Stage B efgartigimod PH20 SC | Stage B placebo PH20 SC |
| --- | --- | --- | --- |
| All-cause mortality, affected/at risk (%) | “2/322 (0.62%)” | “0/111 (0.00%)” | “1/110 (0.91%)” |
| Serious adverse events, affected/at risk (%) | “21/322 (6.52%)” | “6/111 (5.41%)” | “6/110 (5.45%)” |

Source: [ClinicalTrials.gov NCT04281472](https://clinicaltrials.gov/study/NCT04281472?tab=results)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary

Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment; Sanofi states that, in people with CIDP who respond, about 70% of the response is considered incomplete. Approximately two-thirds of patients need long-term intravenous immunoglobulin, and in a US claims analysis 62% of immunoglobulin users were chronic users during the first year after the index date. Biomarkers of disease activity are lacking: in a withdrawal trial, 41% of participants withdrawn from intravenous immunoglobulin remained stable for 24 weeks, compared with 58% who continued it, and the lack of biomarkers can lead to potential overtreatment. After plasma exchange, 8 of 12 responders relapsed within 7 to 14 days of stopping. About 30% of survey respondents receiving intravenous immunoglobulin missed school or work because of infusions, and subcutaneous immunoglobulin typically requires administration once or twice a week. The Gamunex-C prescribing information carries a boxed warning for thrombosis, renal dysfunction, and acute renal failure, and states that renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous products in predisposed patients; observational studies indicate that corticosteroids carry a long-term risk of serious side effects.

Source: [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/); [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444); [van Schaik et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29122523/); [Blein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12896209/); [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957); [Adrichem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166547/); [Hahn et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8813270/); [Allen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854453/); [Hadden et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625974/); [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download); [Hughes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6747552/)

<a id="topic-2.2.2.1.7-2"></a>

###### Non-response and incomplete response to available treatments

> “Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment, highlighting the need for effective alternatives.”

Source: [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/)

> “Approximately 30% of people with CIDP do not respond to standard therapies. In people with CIDP who do respond, about 70% of the response is considered incomplete. Less than one-third of people with CIDP remain in remission without continued therapy.”

Source: [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444)

> “Some patients were dissatisfied by treatment outcomes (11.0%) and symptom control (12.2%). Overall, mean (SD) patient‐reported scores were 62.1 (20.4) for I‐RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ‐5D‐5L.”
> “Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.2.1.7-3"></a>

###### Long-term dependence on immunoglobulin

> “Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin.”

Source: [van Schaik et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29122523/)

> “Of patients who used Ig, 62% ( n = 1,113) were chronic and 38% ( n = 690) were intermittent users during the 1-year post-index.”
> “A substantial proportion of Ig users were chronic users who also received other CIDP therapies, with steroids being most common. This suggests a potentially pronounced burden among patients treated with frequent Ig and steroids.”

Source: [Blein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12896209/)

> “Over 70% of CIDP patients require ongoing treatment with immunosuppressants such as IVIg, S.C. immune globulin, PLEX or steroids.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.2.2.1.7-4"></a>

###### No biomarker of ongoing need for treatment, and overtreatment

> “Biomarkers for disease activity are lacking, making the need for ongoing treatment difficult to assess, leading to potential overtreatment and high health-care costs.”
> “In the intravenous immunoglobulin withdrawal group, 41% remained stable for 24 weeks, compared to 58% in the intravenous immunoglobulin continuation group (−17%; 95% CI −39 to 8).”
> “Of the intravenous immunoglobulin withdrawal group, 28% remained stable at the end of the extension phase.”

Source: [Adrichem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166547/)

> “45/125 individuals met criteria for clinical stability, with median age 58 years, I‐RODS 37/48, MRC‐SS 69/70 and annual treatment costs £107 000/person.”
> “12 of 36 (33.3%) consented to cessation trial and eight of those (66.7%) remained stable off treatment for ≥ 12 months.”

Source: [Koay et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11836592/)

<a id="topic-2.2.2.1.7-5"></a>

###### Relapse after stopping plasma exchange

> “Eight of 12 PE responders (66%) relapsed within 7-14 days after stopping PE.”

Source: [Hahn et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8813270/)

> “Rapid deterioration after plasma exchange occurred in eight of 12 who had improved.”

Source: [Mehndiratta et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6734114/)

<a id="topic-2.2.2.1.7-6"></a>

###### Burden of infusions

> “IVIg was associated with venous access issues and work/school absenteeism.”
> “About 30% of respondents in each group that received IVIg missed school or work because of the infusions”

Source: [Allen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854453/)

> “SCIG has fewer systemic adverse reactions than IVIG and can be administered at home by patients or caregivers, 8 but typically requires more frequent infusions, such as administration once or twice a week.”
> “Mean (standard deviation) infusion duration was 135.5 (62.8) minutes.”

Source: [Hadden et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625974/)

<a id="topic-2.2.2.1.7-7"></a>

###### Safety limitations of immunoglobulin and corticosteroids

> “WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE”
> “Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients.”

Source: [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download)

> “We also know from observational studies that corticosteroids carry the long‐term risk of serious side effects.”

Source: [Hughes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6747552/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

In a US claims analysis of 3,409 individuals with CIDP, 2,758 (81%) were treated during the first year, and steroids (73% of those treated) followed by immunoglobulin (65%) were the most commonly used treatments. Neurology specialists are the most frequent prescribers of immunoglobulin, which may be given in a hospital clinic, physician's office, infusion clinic, or at home; the Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) prefilled syringe may be administered subcutaneously by patients or caregivers after proper instruction, and the vial is to be administered by a healthcare professional only.

The company positions claseprubart as a potential first-line biologic given as a subcutaneous, infrequently dosed, self-administered injection, and CAPTIVATE enrolls standard-of-care-refractory, standard-of-care-treated, and standard-of-care-naive patients without requiring immunoglobulin withdrawal. Other complement inhibitors are in development: Sanofi announced that the phase 3 MOBILIZE trial of riliprubart, an antibody that selectively inhibits activated C1s, in CIDP refractory to standard-of-care treatment will be stopped after an independent data monitoring committee determined at an interim analysis that it is unlikely to provide sufficient efficacy, and that continuation of VITALIZE will be evaluated accordingly; argenx is advancing two phase 3 trials of empasiprubart, an antibody targeting C2, one of them a head-to-head comparison with intravenous immunoglobulin.

Source: [Blein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12896209/); [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957); [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/); [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1); [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9); [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444); [argenx annual report (2026)](https://reports.argenx.com/2025/argenx-group/our-products-and-product-candidates/empasiprubart-development.html)

<a id="topic-2.2.2.2-2"></a>

###### Current US treatment patterns

> “Among patients who received treatment in 2023, a majority in both cohorts received steroids, followed by immunoglobulin.”
> “Patients in both cohorts were most frequently seen by neurology specialists, and these specialists were the most frequent prescribers of immunoglobulin.”

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)

> “Among 3,409 patients with CIDP identified, the majority (81% [ n = 2,758]) were treated for CIDP while 19% ( n = 651) were untreated for CIDP during 1-year post-index. Steroids (73% [ n = 2017]) followed by Ig (65% [ n = 1,803]) were most commonly utilized.”

Source: [Blein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12896209/)

> “Of the 525 patients identified with newly diagnosed CIDP, 55.2% of patients were prescribed only steroid therapy, and 25.3% of patients were prescribed an IVIG therapy during the 2-year follow-up.”

Source: [Guptill et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6611518/)

<a id="topic-2.2.2.2-3"></a>

###### Care setting for current infused and injected therapies

> “Immunoglobulin may be administered at a hospital clinic, physician’s office, free-standing infusion clinic, or at home with proper monitoring”

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)

> “When the costs were evaluated by site of care, home infusion visits were a primary site of care in CIDP-specific costs for the patients receiving IVIG.”

Source: [Guptill et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6611518/)

> “VYVGART HYTRULO prefilled syringe may be administered by patients and/or caregivers after proper instruction in subcutaneous injection technique”
> “VYVGART HYTRULO vial is to be administered with a winged infusion set by a healthcare professional only”

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.2.2.2-4"></a>

###### Company positioning of claseprubart in CIDP

> “Despite treatment, a significant number of patients do not achieve clinical remission and there remains a significant unmet clinical need for this disease. Given the role of the complement system in the disease pathology, patients may benefit from a selective C1s inhibitor.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “Claseprubart has opportunity to compete as a potential 1L biologic in three large and growing US neuromuscular markets”
> “Opportunity for an active C1s inhibitor with the target profile of claseprubart to replace the standard of care Note: Positioning of claseprubart’s target profile is illustrative.”
> “Improvement over SoC (i.e. Ig) with continuous, effective symptom control”
> “Enrolling a broad patient population including SoC- refractory patients, in addition to SoC-Treated and SoC-Naïve patients”
> “No requirement for IVIg withdrawal and disease worsening, consistent with ongoing FcRn and complement CIDP studies”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Claseprubart is designed to enable a more convenient SC, infrequently dosed, self-administered injection.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-2.2.2.2-5"></a>

###### Company-sponsored survey of US neurologists on unmet need

> “Significant unmet need for effective therapies for patients who don’t respond to IVIg75%”
> “IVIg imposes a high treatment burden due to frequent and time-consuming infusions59%”
> “Overall, surveyed Neurologists believe ~50% of patients on IVIg have partial or no response to treatment”
> “Dianthus 2026 Neurologist CIDP and MMN quantitative survey (n=80, N = 65 Neuromuscular specialists, N = 15 General Neurologists), fielded Q1.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.2-6"></a>

###### Investigational complement inhibitors in CIDP

> “Several complement inhibitors are in development for the treatment of CIDP and increasing evidence suggests that activation of the classical complement pathway plays a crucial role in the pathophysiology of CIDP.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-2.2.2.2-7"></a>

###### Riliprubart phase 3 trials: refractory and immunoglobulin-treated populations

> “MOBILIZE, a randomized, double-blind, placebo-controlled trial, targets participants who are presently not on intravenous immunoglobulin (IVIg), and have a history of no/inadequate response to IVIg/corticosteroids.”
> “VITALIZE, a randomized, double-blind, double-dummy, non-inferiority, and superiority design trial with sample size re-estimation will compare riliprubart versus IVIg continuation in IVIg-treated participants, who do not have complete response (i.e. residual disability, even if “stable” on IVIg).”

Source: [Sommer et al. (2026)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-002025.html)

<a id="topic-2.2.2.2-8"></a>

###### Riliprubart MOBILIZE trial stopped for insufficient efficacy

> “Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped.”
> “This decision follows an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study is unlikely to provide sufficient efficacy. No safety signals related to riliprubart were identified as part of this interim analysis.”
> “The continuation of other ongoing studies with riliprubart, including the VITALIZE phase 3 study (clinical study identifier: NCT06290141) in IVIg-treated patients with CIDP, will be evaluated accordingly.”

Source: [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444)

<a id="topic-2.2.2.2-9"></a>

###### Empasiprubart phase 3 trials

> “argenx is advancing two Phase 3 clinical trials of empasiprubart in CIDP: EMVIGORATE and EMNERGIZE. EMVIGORATE is a head‑to‑head clinical trial comparing empasiprubart to IVIg in adults with CIDP. EMNERGIZE is a randomized, placebo‑controlled clinical trial evaluating the efficacy and safety of empasiprubart. Topline results from both EMVIGORATE and EMNERGIZE are expected in the second half of 2027.”
> “empasiprubart is a differentiated therapeutic mAb targeting C2 equipped with our proprietary NHANCE™ mutations.”

Source: [argenx annual report (2026)](https://reports.argenx.com/2025/argenx-group/our-products-and-product-candidates/empasiprubart-development.html)

<a id="topic-2.2.2.2-10"></a>

###### Riliprubart MOBILIZE: refractory population, enrollment, and status in the registry record

> “The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care.”
> “Participant must be refractory to either immunoglobulin therapy or corticosteroid therapy, as defined below.”
> “Immunoglobulin-refractory subgroup: Historic evidence of failure or inadequate response to immunoglobulin therapy prior to screening”
> “Corticosteroid-refractory subgroup: Historic evidence of failure or inadequate response to corticosteroid therapy prior to screening”
> “Primary Completion (Actual) 2026-06-10”
> “Enrollment (Actual) 109”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT06290128](https://clinicaltrials.gov/study/NCT06290128)

<a id="topic-2.2.2.2-11"></a>

###### Riliprubart VITALIZE: population maintained on intravenous immunoglobulin in the registry record

> “The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg.”
> “Participants must have responded to IVIg in the past 5 years.”
> “Participant must be on a stable maintenance dosage of IVIg.”
> “Participants receiving IVIg infusions at home are eligible, as long as IVIg infusions are switched to a hospital or infusion center setting at least 1 cycle prior to baseline.”
> “Enrollment (Estimated) 160”

Source: [ClinicalTrials.gov NCT06290141](https://clinicaltrials.gov/study/NCT06290141)

<a id="topic-2.2.2.2-12"></a>

###### Empasiprubart EMNERGIZE: untreated and treated participants switching to study drug in the registry record

> “Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors)”
> “Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP”
> “Has residual disability and active disease”

Source: [ClinicalTrials.gov NCT07091630](https://clinicaltrials.gov/study/NCT07091630)

<a id="topic-2.2.2.2-13"></a>

###### Empasiprubart EMVIGORATE: population treated with intravenous immunoglobulin in the registry record

> “The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP.”
> “Has responded to IVIg in the past 5 years”
> “Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose of at least 0.125 g/kg”

Source: [ClinicalTrials.gov NCT06920004](https://clinicaltrials.gov/study/NCT06920004)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Typical CIDP and CIDP variants

> “Patients were diagnosed with typical CIDP (69.2%) and variant CIDP (30.8%).”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

> “A diverse and complex interplay of different immunopathological mechanisms, involving cellular, humoral and complement pathways, culminates in a highly variable pattern of peripheral nerve damage in different clinical variants of CIDP.”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

> “Participants must have typical, motor or multifocal CIDP.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-2.2.2.3-2"></a>

###### Antibody-mediated nodopathies: response to standard therapy

> “A breakthrough in CIDP antibody autoimmunity has been the remarkable observation that a subset of patients who do not respond to IVIg or plasmapheresis have IgG4 antibodies to nodal/paranodal antigens directed against neurofascin-155 (Nfasc155), neurofascin-140/186 (Nfasc140/186), contactin-1 (CNTN1), and contactin-associated protein 1 (Caspr1)”
> “Because the IgG4 antibodies do not trigger inflammatory processes or complement-mediated immune responses, the conventional anti-inflammatory therapies, especially with IVIg, immunosuppressants, and plasmapheresis, are ineffective or not sufficiently effective in inducing long-term remissions.”
> “Indeed, data from large series of patients with MuSK myasthenia, CIDP with nodal/paranodal antibodies, and anti-LGI1 and CASPR2-associated syndromes indicate that B cell depletion therapy with rituximab exerts long-lasting clinical remissions by targeting memory B cells and IgG4-producing CD20-positive short-lived plasma cells.”

Source: [Dalakas (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294117/)

<a id="topic-2.2.2.3-3"></a>

###### Antibody subclass and expected relevance of complement inhibition

> “It is noteworthy that almost all the antibodies to these paranodal antigens were IgG4, an IgG subclass that is non-complement fixing”
> “Nonetheless, some variants of these neuropathies harbor IgG1-3 subclass of antibodies with ability to fix complement and could potentially be candidates to complement inhibition”
> “However, complement involvement in certain subgroups of CIDP patients, including those with non-complement fixing antibodies, is not yet certain”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.2.3-4"></a>

###### Response by prior immunoglobulin exposure

> “IVIG-pretreated patients demonstrated a higher responder rate than IVIG-naïve patients (76.9% vs. 46.7%).”

Source: [Léger et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3910165/)

<a id="topic-2.2.2.3-5"></a>

###### Response by disease course to plasma exchange

> “Fifteen patients completed the trial and of those, 12 patients (80%) improved substantially with PE; i.e. five out of seven patients with chronic progressive course and seven out of eight patients with relapsing CIDP improved.”
> “The PE non-responders improved with prednisone.”

Source: [Hahn et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8813270/)

<a id="topic-2.2.2.3-6"></a>

###### Non-response and alternative diagnoses

> “Alternative diagnosis was made in 7 out of 12 (58%) who did not respond to any therapy and in none of the treatment-responsive patients.”
> “In treatment-nonresponsive patients, the diagnosis CIDP should be reconsidered.”

Source: [Eftimov et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22442436/)

<a id="topic-2.2.2.3-7"></a>

###### Activated C1s inhibition by standard-of-care group: riliprubart phase 2

> “This open-label, Phase-2 trial evaluates riliprubart across three groups: Standard-of-care (SoC)-Treated, SoC-Refractory, and SoC-Naïve.”
> “At Week-24, Part-A interim-analysis showed 87% (N=42/48) SoC-Treated participants improved/remained stable (improved: 52%; N=25/48) after directly switching from SoC to riliprubart. 50% (N=9/18) SoC-Refractory, and 75% (N=9/12) SoC-Naïve participants responded to riliprubart”

Source: [Querol et al. (2026d)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-000633.html)

<a id="topic-2.2.2.3-8"></a>

###### Neonatal Fc receptor blockade by prior treatment status

> “Clinically meaningful improvements in disability and strength were observed across assessments, regardless of stage B treatment or prior treatment status, with greater improvements seen over time.”

Source: [Allen et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375598/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Immunoglobulin dose optimization and cessation trials

> “Periodic IVIG optimization trials using objective outcomes are encouraged in all CIDP patients receiving chronic IVIG treatment as a means to identify the lowest effective IVIG dose and frequency.”
> “In both groups, drug‐free remission was achieved in about one‐third of patients.”

Source: [Cook et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10098814/)

> “The successful cessation trials resulted in a cost saving of £855 000/year, with a potential further saving of £1.7 million/year if all the eligible individuals had consented.”
> “All patients who deteriorated were rescued to previous baseline on retreatment.”
> “Individuals with CIDP should be counselled about the natural history of the disease and future scheduled, targeted cessation trials. A dedicated clinical infrastructure is vital to safely perform cessation trials.”

Source: [Koay et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11836592/)

> “Not all patients may require continued maintenance therapy beyond the initial 6 months of therapy in order to maintain their therapeutic response.”

Source: [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download)

<a id="topic-2.2.2.4-2"></a>

###### Subcutaneous immunoglobulin dose reduction

> “After dose reduction from 0.4 to 0.2 g/kg, 51% (27/53) of patients relapsed, of whom 92% (24 of 26) improved after reinitiation of the 0.4 g/kg dose.”
> “Two-thirds of patients (19/28) who completed the PATH study without relapse remained relapse-free on the 0.2 g/kg dose after dose reduction in the extension study.”
> “Long-term dosing should be individualized to find the most appropriate dose in a given patient.”

Source: [van Schaik et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6624149/)

> “If CIDP symptoms worsen, on 0.2 g/kg (1 mL/kg) body weight per week, consider increasing the HIZENTRA dose from 0.2 g/kg to 0.4 g/kg body weight per week.”
> “Monitor patient’s clinical response and adjust duration of therapy based on patient need.”

Source: [Hizentra prescribing information (2021)](https://www.fda.gov/media/78466/download)

<a id="topic-2.2.2.4-3"></a>

###### Home and subcutaneous administration

> “Eight consecutive patients, four with MMN and four with CIDP, already on long-term, hospital-based IVIG were switched to home-based SCIG.”
> “In seven of the eight patients, SCIG gave improved tolerability and patient satisfaction with similar efficacy compared with IVIG.”

Source: [Hadden et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4286942/)

> “The most important factors in treatment decision-making were a lower chance of CIDP symptom worsening in 6 months, less frequent treatment administration, and home infusion (all p < 0.001 vs reference categories).”

Source: [Yang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396306/)

> “In addition, like conventional SCIG, fSCIG 10% offers the potential convenience of home administration, 13 leading to possible cost savings and eliminating burden of travel to an infusion center or other facility over multiple days.”

Source: [Hadden et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625974/)

> “Home infusions are generally safe, effective, convenient, and less costly than infusions in other sites of care (eg, physician office, outpatient hospital), making this a frequently used site of care for infusions, either by choice or through health plan benefit design.”

Source: [Guptill et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6611518/)

<a id="topic-2.2.2.4-4"></a>

###### Outcome monitoring with disability, strength, and patient-reported scales

> “Assessing strength impairment, disability, and quality of life is ideally suited for everyday practice when caring for patients with CIDP.”
> “Such data are critically important when justifying the need for ongoing or periodic immunotherapy, documenting relapse or deterioration, or providing reassurance of disease improvement, stability, or remission.”

Source: [Allen et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32338716/)

> “Frequent assessment of grip strength can be a useful tool to identify intravenous immunoglobulin (IVIG) treatment‐related fluctuations (TRFs) and optimize IVIG treatment in real‐time, but the long‐term implications of TRFs are unknown.”

Source: [Cook et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10098814/)

> “The primary endpoint in stage A, evaluated in the stage A safety population, was confirmed ECI (≥1 points aINCAT decrease, ≥4 points [centile metric] Inflammatory Rasch-built Overall Disability Scale increase, or ≥8 kPa grip strength increase after four injections and two consecutive visits).”

Source: [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/)

<a id="topic-2.2.2.4-5"></a>

###### Remote monitoring of grip strength and patient-reported outcomes

> “Patients were monitored weekly or monthly, based on stability and patient preference, using grip strength, modified timed‐up‐and go (mTUG), and patient‐reported outcome measures (PROMs).”
> “Adherence was 93% (95% CI: 91.9%–94.1%).”
> “Grip strength and mTUG ICCs were both 0.96 (95% CI: 0.93–0.98 and 0.92–0.99, respectively).”

Source: [Lemmen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11915482/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Company target product profile in CIDP

> “Achieving this target profile could position claseprubart as a potential blockbuster treatment for CIDP”
> “Improvement over SoC (i.e. Ig) with continuous, effective symptom control”
> “Comparable safety to FDA-approved C1s & Classical Pathway inhibitor, leaving the lectin and alternative pathways intact”
> “Most convenient therapy with self-administered SHL-Molly autoinjector”
> “Targeting no Boxed Warning & REMS”
> “Targeting single 300mg/2mL self-administered S.C. Q2W”
> “Safety and efficacy for claseprubart has not been evaluated in head-to-head comparative clinical studies.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.7-2"></a>

###### Company statement of expected benefit in CIDP

> “Despite treatment, a significant number of patients do not achieve clinical remission and there remains a significant unmet clinical need for this disease. Given the role of the complement system in the disease pathology, patients may benefit from a selective C1s inhibitor.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.2.2.7-3"></a>

###### Target response rate for the phase 3 interim responder analysis

> “In June 2026, we announced a 75% response rate observed in the Interim Responder Analysis from the first 40 participants completing Part A of the Phase 3 CAPTIVATE trial, exceeding the target response rate of 50% or greater based on precedent set with aC1s inhibition.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
